Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/04—X-ray contrast preparations
  • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
  • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Definitions

• Acute kidney injury is an important clinical problem associated with high rates of morbidity and mortality (1.7 million deaths annually).
• Considerable effort has been directed toward the development of preventive strategies for AKI using various agents and animal models.
• preventive strategies for AKI using various agents and animal models.
• no specific treatment for AKI has yet been developed.
• AKI renal ischemic reperfusion injury
• ATP depletion energy impairment
• ATN acute tubular necrosis
• AKI acute tubular necrosis
• Embodiments described herein relate to compositions and methods of preventing, treating, or reducing the severity of a renal disorder, disease, and/or injury. It was found that administration of a 15-PGDH inhibitor to a subject prior to and/or after renal injury can induce renal vasodilation, and enhance resistance to hypoxia resulting in a prophylactic and protective effect against renal injury. These benefits can be associated with a prophylactic use of as little as a single dose of a 15-PGDH inhibitor. Administration of a 15-PGDH inhibitor to a subject having or at risk of a renal injury improved renal hemodynamics, decreased induction of oxidative stress, reduced induction of inflammation, attenuated multiple markers of renal damage and preserved renal function.
• compositions and methods of inhibiting 15-PDGH activity can be used to prevent, treat, or reduce the severity of a renal disorder, disease, and/or injury in a subject and/or kidney of a subject in need thereof.
• renal disorders, diseases, and/or injuries that can be treated include hypotensive injury to the kidney; hypertensive renal disease; diabetic renal disease and diabetic nephropathy; renal disease from vasculitis and autoimmune diseases, including but not limited to lupus erythematosis, polyarteritis, Wegeners’ Granulomatosis, and mixed connective tissue disease; ischemic renal injury; acute renal failure; chronic renal failure; glomerulonephritis; nephrotic syndrome; acute tubular necrosis; nephrosclerosis; gomerulosclerosis; minimal change disease; idiopathic membranous nephropathy; membranoproliferative glomerulonephritis; Berger’s disease; mesangial proliferative glomerulonephritis; chronic glomerulonephritis; focal glomerulosclerosis; renal effects of Sjogren’s syndrome; renal effects of scleroderma; interstitial n
• the amount of 15-PGDH inhibitor administered to a subject can be an amount effective to induce endogenous renal PGE2 levels of the subject.
• the amount of 15-PGDH inhibitor administered to a subject can be an amount effective to induce renal vasodilatation, enhance resistance to hypoxia, improve renal hemodynamics, decrease renal oxidative stress, reduce renal inflammation, and preserve renal function.
• the amount of 15-PGDH inhibitor administered to a subject is an amount effective to reduce malondialdehyde (MDA) and NGAL levels, attenuate medulla tubular damage, reduce medulla acute tubular necrosis (ATN) and apoptosis, reduce induction of high-mobility group box 1 (HMGB1) and proinflammatory cytokines, induce renal EP4 PGE2 receptors and A2A adenosine receptors in vascular smooth muscle cells that regulate renal arterioles, increase renal cAMP, AMP, and adenosine levels, and/or inhibit induction of creatinine and KIM-1.
• MDA malondialdehyde
• NGAL levels attenuate medulla tubular damage
• ATN medulla acute tubular necrosis
• HMGB1 high-mobility group box 1
• proinflammatory cytokines induce renal EP4 PGE2 receptors and A2A adenosine receptors in vascular smooth muscle cells that regulate renal
• the 15-PGDH inhibitor can be administered to a subject before a renal injury.
• the 15-PGDH inhibitor can be administered at a range of about 1 minute to about 72 hours, about 10 minutes to about 48 hours, or about 30 minutes to about 36 hours before a renal disorder, disease, and/or injury.
• the 15-PGDH inhibitor can be administered at a time selected from less than about 2 hours, less than about 8 hours, less than about 24 hours, and less than about 26 hours before the renal disorder, disease, and/or injury.
• the renal disorder, disease, and/or injury is associated with an organ transplant, such as a kidney transplant, in the subject.
• the renal disorder, disease, and/or injury is associated with cardiovascular surgery or sepsis.
• the renal disorder, disease, and/or injury is a contrast- induced acute kidney injury (CIAKI).
• CIAKI contrast- induced acute kidney injury
• the 15-PGDH inhibitor can include a compound having the following formula (V): pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein n is 0-2
• X 6 is independently is N or CR C
• R 1 , R 6 , R 7 , and R c are the same or different each independently hydrogen or a substituted or unsubstituted group selected from C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms, C6-C24 alkaryl, C6-C24 aralkyl, halo, -Si(Ci-C3 alkyl)3, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alkynyloxy, C5-C20 aryloxy, acyl, acyloxy, C2-C24 alkoxycarbonyl, C6-C20 aryloxycarbonyl, C2-C24 alkylcarbonato, C6-C20 arylcarbonato, carboxy, carboxylato, carb
• the 15-PGDH inhibitor can inhibit the enzymatic activity of recombinant 15-PGDH at an IC50 of less than 1 mM, or preferably at an IC50 of less than 250 nM, or more preferably at an IC50 of less than 50 nM, or more preferably at an IC50 of less than 10 nM, or more preferably at an IC50 of less than 5 nM at a recombinant 15-PGDH concentration of about 5 nM to about 10 nM.
• Figs. l(A-I) illustrate a schematic and plots showing 15-hydoxyprostaglandin dehydrogenase (15-PGDH) inhibition with renal ischemia-reperfusion ( I/R) injury (IRI) decreases levels of renal injury biomarkers.
• A the arachidonic acid prostaglandin (PG) biosynthesis pathway and biological activity of 15-PGDH inhibitor.
• Cox cyclooxygenase
• NS AIDs nonsteroidal anti- inflammatory drugs.
• B chemical structure of SW033291.
• C pharmacological inhibition of 15-PGDH with SW033291 was confirmed by endogenous PGE2 levels in kidney tissue at 3 h after intraperitoneal injection of 2.5 or 5 mg/kg SW033291 or vehicle.
• D PGE2 levels in kidney tissue at 1 and 3 h after intraperitoneal injection of 5 mg/kg SW033291 or vehicle.
• E experimental setup. Mice were subjected to bilateral renal IRI for 30 min and were injected with vehicle, SW033291, or indo- methacin at 1 h before, immediately after, and 12 h after renal IRI.
• Figs. 2(A-E) illustrate images and plots showing 15-hydoxyprostaglandin dehydrogenase inhibition ameliorates renal tubular cell death in mice with ischemic acute kidney injury.
• IRI renal ischemia-reperfusion injury
• mice were injected intraperitoneally three times with vehicle, SW033291 (5 mg/kg), or indomethacin (5 mg/kg).
• SW033291 5 mg/kg
• indomethacin 5 mg/kg
• A representative gross appearance of the right (Rt) and left (Lt) kidneys of mice injected with vehicle (IRI- vehicle), indomethacin (IRI-indomethacin), or SW033291 (IRI-SW033291) before and after renal IRI.
• Vascular congestion in the renal medulla is indicated by white arrows.
• FIGs. 3(A-H) illustrate plots and a western blot showing 15-hydoxyprostaglandin dehydrogenase inhibitor pretreatment ameliorates the inflammatory response in mice with ischemic acute kidney injury.
• IRI renal ischemia-reperfusion injury
• mice were injected intraperitoneally three times with vehicle, SW033291 (5 mg/kg), or indomethacin (5 mg/kg).
• SW033291 5 mg/kg
• indomethacin 5 mg/kg
• Assessments were performed at 24 h after renal IRI.
• a F proinflammatory cytokine mRNA by real-time PCR (A-C) and protein levels by ELISA (D- F).
• a and D IL-17;
• B and E TNF-a;
• C and F IL-Ib.
• G Western blots of high-mobility group box 1 (HMGB1; 29 kDa) in kidney tissue (representative of three experiments).
• n 9 animals/group. Data are presented as means ⁇ SE. Analysis was performed using Student’s t test.
• Figs. 4(A-D) illustrate plots and images showing 15-hydoxyprostaglandin dehydrogenase inhibition induces renal vasodilation in the outer medulla of mice with ischemic acute kidney injury.
• the inner arteriolar area in the outer medulla was identified by a-smooth muscle actin staining.
• Assessments were performed at postoperative day 1 (POD1), 24 h after renal ischemia-reperfusion injury (IRI).
• A representative images of the change in renal blood flow, as assessed by renal Doppler flux, with administration of vehicle, indomethacin, and SW033291.
• B statistical analysis of renal blood flow in sham animals at time 0, in sham animals administered SW033291 (sham- SW033291) at 1 h post-administration of drug, and in cohorts subject to IRI and administered vehicle, indomethacin, and SW033291, which were then assayed at 24 h post-IRI.
• D statistical analysis of the inner arteriolar area of the outer medulla. Data are presented as means ⁇ SE. Analysis was performed using Student’s t test.
• Figs. 5(A-G) illustrate plots, a western blot, and images showing 15- hydoxyprostaglandin dehydrogenase inhibitor promoted adenosine production and upregulated the expression of adenosine A2 A receptors in the renal arterioles in the outer medulla via the cAMP/AMP signaling pathway.
• Assessments were performed at 24 h after renal ischemia-reperfusion injury (IRI).
• E Western blots for A2 A receptor protein (45 kDa) in kidney tissue (representative of three experiments).
• G representative confocal microscopy images of kidneys immunostained for A2 A receptor and a-smooth muscle actin (a-SMA).
• FIGs. 6(A-L) illustrate plots, a western blot, and images showing 15- hydoxyprostaglandin dehydrogenase inhibitor treatment promoted the expression of EP4 receptors in the renal arteriolar outer medulla. Assessments were performed at 24 h after renal ischemia-reperfusion injury (IRI).
• a D statistical analysis of EPi (A), EP2 (B), EP3 (C), and EP4 (D) receptor mRNA levels in kidney tissue by real-time PCR.
• n 6-10 animals/group.
• E Western blots for EP4 receptor protein (73 kDa) in kidney tissue (representative of three experiments).
• G representative confocal microscopy images for EP4 receptors (green), a-smooth muscle actin (a-SMA; red), and DAPI (blue)-stained kidney sections.
• H-L effects of the EP4 inhibitor ONO-AE3- 208 on SW033291 amelioration of IRI- induced renal injury. Data are presented as means ⁇ SE. Analysis was performed using Student’s t test.
• Figs. 7(A-F) illustrate plots showing 15-hydoxyprostaglandin dehydrogenase inhibitor pretreatment mitigates renal dysfunction after renal ischemia-reperfusion injury (IRI).
• A experimental setup for the three different injection protocols. Mice were injected with vehicle or SW033291 (5 mg/kg) according to three different injection protocols. Renal function was assessed at 24 h after renal IRI.
• F renal blood flow. Data are presented as means ⁇ SE. Analysis was performed with Student’s t test.
• Figs. 8(A-H) illustrate plots showing pretreatment with a single dose of 15- hydoxyprostaglandin dehydrogenase inhibitor attenuates the increase of PGE2 level and renal damage after renal ischemia-reperfusion injury (IRI). Shown are expression changes of related factors in renal tissue or serum after ischemic acute kidney injury.
• A malondialdehyde (MDA) levels in kidney tissue.
• B-D neutrophil gelatinase-associated lipocalin (NGAL; B), kidney injury molecule- 1 (KIM-1; C), and creatinine (D) levels in serum.
• E and F renal PGE2 levels (E) and serum PGE2 levels (F).
• Fig. 9 illustrates a schematic mechanism of intrarenal vasodilation by the 15- hydoxyprostaglandin dehydrogenase (15-PGDH) inhibitor (PGDH-i) in ischemic acute kidney injury.
• 15-PGDH inhibitor pretreatment increases endogenous PGE2 by inhibiting degradation of PGE2 prior to an ischemic event in the kidney.
• Endogenous PGE2 induces vasodilation through the activated EP4 receptor.
• Activation of EP4 receptors increases the intracellular cAMP level in vascular smooth muscle cells and the effect on vasodilation.
• Increased cAMP is converted to the adenosine (ADO) substrate AMP, which, in turn, increases the endovascular adenosine level.
• ADO activates A2 A receptors to induce vasodilation.
• nonsteroidal anti-inflammatory drugs NSAIDs
• cyclooxygenase cox
• AA arachidonic acid
• ePDE extracellular phosphodiesterase
• RBC red blood cell.
• FIG. 10 illustrate a table, schematic, and graphs showing an establishment of contrast induced acute kidney injury (CIAKI).
• CIAKI contrast induced acute kidney injury
• FIGs. 11 illustrate plots and a schematic showing 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibition of contrast- induced acute kidney injury decreases the levels of renal injury biomarkers.
• PGE2 Prostaglandin E2
• FIG. 11 illustrates plots and a schematic showing 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibition of contrast- induced acute kidney injury decreases the levels of renal injury biomarkers.
• PGE2 Prostaglandin E2
• mice received SW033291, PGE1, PGE2, or vehicle at 1 h before, immediately after, and 8, 16, and 24 h after administration of 10 gEkg iodixanol.
• C-E Serum levels of creatinine, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule- 1 (KIM-1), respectively. Renal function was evaluated at 48 h after contrast medium (CM) injection. *p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001.
• FIGs. 12(A-E) illustrate images and a plot showing 15-hydroxyprostaglandin dehydrogenase inhibition ameliorates renal tubular cell death in contrast-induced acute kid ney injury mice.
• CM contrast medium
• mice were injected intraperitoneally with a vehicle, SW033291 (15-PGDH inhibitor; 5 mg/kg), prostaglandin Ei (PGE1; 20 mg/kg), or PGE2 (5 mg/kg).
• PGE1 prostaglandin Ei
• PGE2 5 mg/kg
• Assessments were performed at 48 h after intravenous CM injection.
• A Representative gross appearances of the left and right kidneys of normal mice, and of those after injection with CM vehicle, CM SW033291, CM PGE1, or CM PGE2. Renal congestion in the outer medullary region is indicated by a black arrow.
• FIG. 1 Representative images of tubular injury in the outer zone of the renal medulla (hematoxylin and eosin staining). Scale bars in small panels, 500 lm and those in enlarged images, 50 pm.
• D Representative images of apoptosis in the outer zone of the renal medulla (terminal deoxynucleotidyl transferase dUTP nick end labeling staining). Scale bars in small panels, 500 pm, those in enlarged images, 25 pm.
• FIG. 13(A-C) illustrate images and a graph showing 15-hydroxyprostaglandin dehydrogenase inhibitor effects on iodixanol-induced apoptosis in human renal proximal tubular epithelial cells (hRPTECs).
• hRPTECs were treated with SW033291 (15-PGDH inhibitor), prostaglandin Ei (PGE1), or PGE2 simultaneously with Visipaque (iodixanol 50 mgl/mL).
• A Representative pictures of hRPTECs viability 24 h after Visipaque (iodixanol 50 mg I/m L) treatment.
• B Quantification of hRPTEC viability by MTT assay.
• C Quantification of hRPTECs apoptosis by flow cytometry; *p ⁇ 0.05; **p ⁇ 0.001.
• CM contrast medium.
• Figs. 14(A-F) illustrate images and plots showing 15-hydroxyprostaglandin dehydrogenase inhibition induces renal vasodilation in the outer medulla via the adenosine monophosphate (AMP)-adenosine signaling pathway.
• A Representative images of arterioles in the outer zone of the renal medulla. Magnified images are enlargements of the outlined areas.
• B Statistical analyses of the inner arteriole area of the outer medulla.
• C Statistical analyses of renal blood flow following administration of a vehicle, SW033291 (inhibitor), prostaglandin Ei (PGE1), or PGE2 in contrast-induced acute kidney injury mice.
• Fig. 15(A-H) illustrate plots showing 15-hydroxyprostaglandin dehydrogenase inhibition changes the level of prostaglandin E2 (PGE2) receptor (EP) expression in kidney tissue.
• PGE2 prostaglandin E2
• EP prostaglandin E2
• SW033291 The protective effects of thel5-PGDH inhibitor, SW033291, can be blocked by an EP4 antagonist, ONO-AE3-208.
• A-D Statistical analyses of the EP expression level.
• E- G Seram levels of creatinine, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1) due to the absence or presence of ONO-AE3-208 in the contrast- induced acute kidney injury model.
• H Statistical analyses of renal blood flow p ⁇ 0.05; p ⁇ 0.01; p ⁇ 0.001; CM: contrast medium.
• pharmaceutically acceptable means suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use within the scope of sound medical judgment.
• salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc.
• acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
• salts also includes those obtained by reacting the active compound functioning as an acid, with an inorganic or organic base to form a salt, for example salts of ethylenediamine, N-methyl- glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris-(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, and the like.
• Non limiting examples of inorganic or metal salts include lithium, sodium, calcium, potassium, magnesium salts and the like.
• the salts of the compounds described herein can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules.
• Non-limiting examples of hydrates include monohydrates, dihydrates, etc.
• Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.
• solvates means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H2O, such combination being able to form one or more hydrate.
• the compounds and salts described herein can exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and geometric isomers and mixtures thereof.
• Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer predominates. Even though one tautomer may be described, the present application includes all tautomers of the present compounds.
• a tautomer is one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another. This reaction results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that are interconvertable by tautomerizations is called tautomerism.
• keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs.
• Tautomerizations can be catalyzed by: Base: 1. deprotonation; 2. formation of a delocalized anion (e.g., an enolate); 3. protonation at a different position of the anion; Acid:
• Halo or “halogen” refers to bromo, chloro, fluoro or iodo radical.
• Haldroxy or “hydroxyl” refers to the -OH radical.
• Niro refers to the -NO 2 radical.
• Alkyl or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain radical having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C 1 -C 12 alkyl, an alkyl comprising up to 10 carbon atoms is a C 1 -C 10 alkyl, an alkyl comprising up to 6 carbon atoms is a C 1 -C 6 alkyl and an alkyl comprising up to 5 carbon atoms is a C 1 -C 5 alkyl.
• a Ci- C 5 alkyl includes C 5 alkyls, C 4 alkyls, C 3 alkyls, C 2 alkyls and Ci alkyl (i.e., methyl).
• a Ci- Ce alkyl includes all moieties described above for C 1 -C 5 alkyls but also includes C6 alkyls.
• a C 1 -C 10 alkyl includes all moieties described above for C 1 -C 5 alkyls and C 1 -C 6 alkyls, but also includes C 7 , Cs, C 9 and C 10 alkyls.
• a C 1 -C 12 alkyl includes all the foregoing moieties, but also includes Cn and C 12 alkyls.
• Non-limiting examples of C 1 -C 12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec -butyl, t-butyl, n-pentyl, t- amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl.
• an alkyl group can be optionally substituted.
• Alkylene or “alkylene chain” refers to a fully saturated, straight or branched divalent hydrocarbon chain radical, and having from one to twelve carbon atoms.
• C 1 -C 12 alkylene include methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like.
• the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
• alkylene chain can be optionally substituted.
• alkenyl or “alkenyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl group comprising any number of carbon atoms from 2 to 12 are included.
• An alkenyl group comprising up to 12 carbon atoms is a C2-C12 alkenyl
• an alkenyl comprising up to 10 carbon atoms is a C2-C10 alkenyl
• an alkenyl group comprising up to 6 carbon atoms is a C2-C6 alkenyl
• an alkenyl comprising up to 5 carbon atoms is a C2-C5 alkenyl.
• a C2- C5 alkenyl includes C5 alkenyls, C4 alkenyls, C3 alkenyls, and C2 alkenyls.
• a C2- , alkenyl includes all moieties described above for C2-C5 alkenyls but also includes Ce alkenyls.
• a C2- C10 alkenyl includes all moieties described above for C2-C5 alkenyls and C2-C6 alkenyls, but also includes C7, Cs, C9 and C10 alkenyls.
• a C2-C12 alkenyl includes all the foregoing moieties, but also includes C11 and C12 alkenyls.
• Non-limiting examples of C2-C12 alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-l- propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1- hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4- heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6- octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-non
• alkenylene or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon double bonds.
• C2-C12 alkenylene include ethene, propene, butene, and the like.
• the alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
• the points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.
• Alkynyl or “alkynyl group” refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl group comprising any number of carbon atoms from 2 to 12 are included.
• An alkynyl group comprising up to 12 carbon atoms is a C 2 -C 12 alkynyl
• an alkynyl comprising up to 10 carbon atoms is a C 2 -C 10 alkynyl
• an alkynyl group comprising up to 6 carbon atoms is a C 2 -
• alkynyl and an alkynyl comprising up to 5 carbon atoms is a C 2 -C 5 alkynyl.
• a C 2 -C 5 alkynyl includes C 5 alkynyls, C 4 alkynyls, C 3 alkynyls, and C 2 alkynyls.
• a C 2 - , alkynyl includes all moieties described above for C 2 -C 5 alkynyls but also includes Ce alkynyls.
• a C 2 -C 10 alkynyl includes all moieties described above for C 2 -C 5 alkynyls and C 2 -C 6 alkynyls, but also includes C 7 , Cs, C 9 and C 10 alkynyls.
• a C 2 -C 12 alkynyl includes all the foregoing moieties, but also includes C 11 and C 12 alkynyls.
• Non-limiting examples of C 2 -C 12 alkenyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
• Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain radical, having from two to twelve carbon atoms, and having one or more carbon-carbon triple bonds.
• C 2 -C 12 alkynylene include ethynylene, propargylene and the like.
• the alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
• the points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted.
• Alkoxy refers to a radical of the formula -OR a where R a is an alkyl, alkenyl or alknyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.
• Alkylamino refers to a radical of the formula -NHR a or -NR a R a where each R a is, independently, an alkyl, alkenyl or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group can be optionally substituted.
• R a is an alkyl, alkenyl or alkynyl radical as defined above.
• a non-limiting example of an alkyl carbonyl is the methyl carbonyl (“acetal”) moiety.
• Alkylcarbonyl groups can also be referred to as “C w -C z acyl” where w and z depicts the range of the number of carbon in R a , as defined above.
• Ci-Cio acyl refers to alkylcarbonyl group as defined above, where R a is Ci-Cio alkyl, C2-C10 alkenyl, or C2-C10 alkynyl radical as defined above. Unless stated otherwise specifically in the specification, an alkyl carbonyl group can be optionally substituted.
• Aryl refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring.
• the aryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems.
• Aryl radicals include, but are not limited to, aryl radicals derived from phenyl (benzene), aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, chrysene, fluoranthene, fluorene, a.v-indacene, .v-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
• aryl is meant to include aryl radicals that are optionally substituted.
• “Aralkyl” or “arylalkyl” refers to a radical of the formula -R t> -R c where R b is an alkylene group as defined above and R c is one or more aryl radicals as defined above.
• Aralkyl radicals include, but are not limited to, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group can be optionally substituted.
• alkenyl or “arylalkenyl” refers to a radical of the formula -R b -R c where R b is an alkenylene group as defined above and R c is one or more aryl radicals as defined above. Unless stated otherwise specifically in the specification, an aralkenyl group can be optionally substituted.
• Alkynyl or “arylalkynyl” refers to a radical of the formula -R b -R c where R b is an alkynylene group as defined above and R c is one or more aryl radicals as defined above. Unless stated otherwise specifically in the specification, an aralkynyl group can be optionally substituted.
• Carbocyclyl refers to a ring structure, wherein the atoms which form the ring are each carbon. Carbocyclic rings can comprise from 3 to 20 carbon atoms in the ring. Carbocyclic rings include aryls and cycloalkyl. Cycloalkenyl and cycloalkynyl as defined herein. Unless stated otherwise specifically in the specification, a carbocyclyl group can be optionally substituted.
• Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon radical consisting solely of carbon and hydrogen atoms, which can include fused, bridged, or spiral ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond.
• Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
• Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.
• Cycloalkenyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, which can include fused, bridged, or spiral ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond.
• Monocyclic cycloalkenyl radicals include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cycloctenyl, and the like.
• Polycyclic cycloalkenyl radicals include, for example, bicyclo[2.2.1]hept-2-enyl and the like. Unless otherwise stated specifically in the specification, a cycloalkenyl group can be optionally substituted.
• Cycloalkynyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, which can include fused, bridged, or spiral ring systems, having from three to twenty carbon atoms, preferably having from three to ten carbon atoms, and which is attached to the rest of the molecule by a single bond.
• Monocyclic cycloalkynyl radicals include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkynyl group can be optionally substituted.
• Cycloalkylalkyl refers to a radical of the formula -R b -R d where R b is an alkylene, alkenylene, or alkynylene group as defined above and R d is a cycloalkyl, cycloalkenyl, cycloalkynyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group can be optionally substituted.
• Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 ,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.
• Haloalkenyl refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropenyl, 1,1-difluorobutenyl, and the like. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
• Haloalkynyl refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., 1-fluoropropynyl, 1-fluorobutynyl, and the like. Unless stated otherwise specifically in the specification, a haloalkynyl group can be optionally substituted.
• Heterocyclyl refers to a stable 3- to 20-membered non-aromatic, partially aromatic, or aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Heterocyclycl or heterocyclic rings include heteroaryls as defined below.
• the heterocyclyl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, and spiral ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl radical can be partially or fully saturated.
• heterocyclyl radicals include, but are not limited to, aziridinyl, oextanyl, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiomorph
• heterocyclyl The point of attachment of the heterocyclyl, heterocyclic ring, or heterocycle to the rest of the molecule by a single bond is through a ring member atom, which can be carbon or nitrogen. Unless stated otherwise specifically in the specification, a heterocyclyl group can be optionally substituted.
• Heterocyclylalkyl refers to a radical of the formula -R t> -R e where R b is an alkylene group as defined above and R e is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group can be optionally substituted.
• Heterocyclylalkenyl refers to a radical of the formula -R b -R e where R b is an alkenylene group as defined above and R e is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocyclylalkenyl group can be optionally substituted.
• Heterocyclylalkynyl refers to a radical of the formula -R b -R e where R b is an alkynylene group as defined above and R e is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocyclylalkynyl group can be optionally substituted.
• V-heterocyclyl refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, a /V-heterocyclyl group can be optionally substituted.
• Heteroaryl refers to a 5- to 20-membered ring system radical one to thirteen carbon atoms and one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, as the ring member.
• the heteroaryl radical can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems, wherein at least one ring containing a heteroatom ring member is aromatic.
• the nitrogen, carbon or sulfur atoms in the heteroaryl radical can be optionally oxidized and the nitrogen atom can be optionally quaternized.
• Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo
• V-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an /V-heteroaryl group can be optionally substituted.
• Heteroarylalkyl refers to a radical of the formula -R b -R f where R b is an alkylene chain as defined above and R f is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group can be optionally substituted.
• Heteroarylalkenyl refers to a radical of the formula -R b -R f where R b is an alkenylene, chain as defined above and R f is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkenyl group can be optionally substituted.
• Heteroarylalkynyl refers to a radical of the formula -R b -R f where R b is an alkynylene chain as defined above and R f is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkynyl group can be optionally substituted.
• Thioalkyl refers to a radical of the formula -SR a where R a is an alkyl, alkenyl, or alkynyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group can be optionally substituted.
• substituted means any of the above groups (e.g., alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, alkylcarbonyl, thioalkyl, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, heterocyclyl, V-heterocyclyl, heterocyclylalkyl, heteroaryl, V-heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, etc) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups
• “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
• “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with -NR g R h ,
• R g and R h are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, /V-heterocyclyl, heterocyclylalkyl, heteroaryl, /V-heteroaryl and/or heteroarylalkyl.
• “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, /V-heterocyclyl, heterocyclylalkyl, heteroaryl, N- heteroaryl and/or heteroarylalkyl group.
• each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.
• a point of attachment bond denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the point of attachment bond and the other of which is not depicted as being attached to the point of attachment bond.
• a point of attachment bond indicates that the chemical entity “A” is bonded to another chemical entity via the point of attachment bond.
• the specific point of attachment to the non-depicted chemical entity can be specified by inference.
• the compound F infers that the point of attachment bond is the bond by which X is depicted as being attached to the phenyl ring at the ortho position relative to fluorine.
• parenteral administration and “administered parenterally” are art-recognized terms, and include modes of administration other than enteral and topical administration, such as injections, and include, without limitation, intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
• treating includes inhibiting a disease, disorder or condition in a subject, e.g., impeding its progress; and relieving the disease, disorder or condition, e.g., causing regression of the disease, disorder and/or condition. Treating the disease or condition includes ameliorating at least one symptom of the particular disease or condition, even if the underlying pathophysiology is not affected.
• preventing is art-recognized and includes stopping a disease, disorder or condition from occurring in a subject, which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it. Preventing a condition related to a disease includes stopping the condition from occurring after the disease has been diagnosed but before the condition has been diagnosed.
• a "patient,” “subject,” or “host” to be treated by the subject method may mean either a human or non-human animal, such as a mammal, a fish, a bird, a reptile, or an amphibian.
• the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent.
• the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
• the subject is a mammal.
• a patient refers to a subject afflicted with a disease or disorder.
• prophylactic or therapeutic treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
• the unwanted condition e.g., disease or other unwanted state of the host animal
• therapeutic agent include molecules and other agents that are biologically, physiologically, or pharmacologically active substances that act locally or systemically in a patient or subject to treat a disease or condition.
• the terms include without limitation pharmaceutically acceptable salts thereof and prodrugs.
• agents may be acidic, basic, or salts; they may be neutral molecules, polar molecules, or molecular complexes capable of hydrogen bonding; they may be prodrugs in the form of ethers, esters, amides and the like that are biologically activated when administered into a patient or subject.
• terapéuticaally effective amount or “pharmaceutically effective amount” is an art-recognized term.
• the term refers to an amount of a therapeutic agent that produces some desired effect at a reasonable benefit/risk ratio applicable to any medical treatment.
• the term refers to that amount necessary or sufficient to eliminate, reduce or maintain a target of a particular therapeutic regimen.
• the effective amount may vary depending on such factors as the disease or condition being treated, the particular targeted constructs being administered, the size of the subject or the severity of the disease or condition.
• One of ordinary skill in the art may empirically determine the effective amount of a particular compound without necessitating undue experimentation.
• a therapeutically effective amount of a therapeutic agent for in vivo use will likely depend on a number of factors, including: the rate of release of an agent from a polymer matrix, which will depend in part on the chemical and physical characteristics of the polymer; the identity of the agent; the mode and method of administration; and any other materials incorporated in the polymer matrix in addition to the agent.
• ED50 means the dose of a drug, which produces 50% of its maximum response or effect, or alternatively, the dose, which produces a pre-determined response in 50% of test subjects or preparations.
• LD50 means the dose of a drug, which is lethal in 50% of test subjects.
• therapeutic index is an art-recognized term, which refers to the therapeutic index of a drug, defined as LD50/ED50.
• IC50 half maximal inhibitory concentration
• compositions are described as having, including, or comprising, specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components.
• methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps.
• order of steps or order for performing certain actions is immaterial so long as the compositions and methods described herein remains operable. Moreover, two or more steps or actions can be conducted simultaneously.
• gene expression includes any information pertaining to the amount of gene transcript or protein present in a sample, as well as information about the rate at which genes or proteins are produced or are accumulating or being degraded (e.g., reporter gene data, data from nuclear runoff experiments, pulse-chase data etc.). Certain kinds of data might be viewed as relating to both gene and protein expression. For example, protein levels in a cell are reflective of the level of protein as well as the level of transcription, and such data is intended to be included by the phrase "gene or protein expression information”.
• Such information may be given in the form of amounts per cell, amounts relative to a control gene or protein, in unitless measures, etc.; the term “information” is not to be limited to any particular means of representation and is intended to mean any representation that provides relevant information.
• expression levels refers to a quantity reflected in or derivable from the gene or protein expression data, whether the data is directed to gene transcript accumulation or protein accumulation or protein synthesis rates, etc.
• the terms "healthy” and “normal” are used interchangeably herein to refer to a subject or particular cell or tissue that is devoid (at least to the limit of detection) of a disease condition.
• nucleic acid refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA).
• DNA deoxyribonucleic acid
• RNA ribonucleic acid
• the term should also be understood to include analogues of either RNA or DNA made from nucleotide analogues, and, as applicable to the embodiment being described, single-stranded (such as sense or antisense) and double- stranded polynucleotides.
• nucleic acid refers to inhibitory nucleic acids. Some categories of inhibitory nucleic acid compounds include antisense nucleic acids, RNAi constructs, and catalytic nucleic acid constructs. Such categories of nucleic acids are well-known in the art.
• Embodiments described herein relate to compositions and methods of preventing, treating, or reducing the severity of a renal disorder, disease, and/or injury. It was found that administration of a 15-PGDH inhibitor to a subject prior to and/or after renal injury can induce renal vasodilation, and enhance resistance to hypoxia resulting in a prophylactic and protective effect against renal injury. These benefits can be associated with a prophylactic use of as little as a single dose of a 15-PGDH inhibitor. Administration of a 15-PGDH inhibitor to a subject having or at risk of a renal injury improved renal hemodynamics, decreased induction of oxidative stress, reduced induction of inflammation, attenuated multiple markers of renal damage and preserved renal function.
• a 15-PGDH inhibitor before and/or after administration of a contrast media was found to prevent and/or treat contrast-induced acute kidney injury (CIAKI).
• CIAKI contrast-induced acute kidney injury
• the administration of a 15-PGDH inhibitor systemically to generate endogenous renal PGE2 in a subject with a renal injury showed greater effectiveness in treating the renal injury than systemic administration of PGE1 or PGE2.
• compositions and methods of inhibiting 15- PDGH activity can be used to prevent, treat, or reduce the severity of a renal disorder, disease, and/or injury in a subject or kidney of a subject in need thereof.
• renal disorders, diseases, and/or injuries include hypotensive injury to the kidney; hypertensive renal disease; diabetic renal disease and diabetic nephropathy; renal disease from vasculitis and autoimmune diseases, including but not limited to lupus erythematosis, polyarteritis, Wegeners’ Granulomatosis, and mixed connective tissue disease; ischemic renal injury; acute renal failure; chronic renal failure; glomerulonephritis; nephrotic syndrome; acute tubular necrosis; nephrosclerosis; gomerulosclerosis; minimal change disease; idiopathic membranous nephropathy; membranoproliferative glomerulonephritis; Berger’s disease; mes
• the subject has been identified as having an acute kidney injury (AKI) based on the Acute Kidney Injury Network (AKIN) criteria or Risk/Injury /Failure/Loss/ESRD (RIFLE) criteria.
• AKI acute kidney injury
• RAFLE Risk/Injury /Failure/Loss/ESRD
• the subject has been identified as having an elevated level of serum creatinine, plasma creatinine, urine creatinine, or blood urea nitrogen (BUN), compared to a healthy control subject.
• BUN blood urea nitrogen
• the subject has been identified as having an elevated level of serum or urine neutrophil gelatinase-associated lipocalin, serum or urine interleukin- 18, serum or urine cystatin C, or urine KIM-1, compared to a healthy control subject.
• the renal disorder, disease, and/or injury is an acute kidney injury. In other embodiments, the renal disorder, disease, and/or injury is an ischemic acute kidney injury.
• the subject is a human who has been identified as having reduced effective arterial volume. In one embodiment, the subject has been identified as having intravascular volume depletion (e.g., due to hemorrhage, gastrointestinal loss, renal loss, skin and mucous membrane loss, nephrotic syndrome, cirrhosis, or capillary leak). In one embodiment, the subject has been identified as having reduced cardiac output (e.g., due to cardiogenic shock, pericardial disease, congestive heart failure, valvular heart disease, pulmonary disease, or sepsis).
• the subject has been identified as having systemic vasodilation (e.g., caused by cirrhosis, anaphylaxis, or sepsis).
• the subject has been identified as having renal vasoconstriction (e.g., caused by early sepsis, hepatorenal syndrome, acute hypercalcemia, a drug, or a radiocontrast agent).
• the renal disorder, disease, and/or injury is a nephrotoxic kidney injury.
• the human subject has been exposed to a nephrotoxin.
• the nephrotoxin can be a nephrotoxic drug selected from the group consisting of an antibiotic (e.g., an aminoglycoside), a chemotherapeutic agent (e.g., cis -platinum), a calcineurin inhibitor, amphotericin B, and a radiographic contrast agent, such as an iodinated contrast media (e.g., Iodixanol or Iobitridol).
• an antibiotic e.g., an aminoglycoside
• a chemotherapeutic agent e.g., cis -platinum
• a calcineurin inhibitor e.g., amphotericin B
• a radiographic contrast agent such as an iodinated contrast media (e.g., Iodixanol or Iobitridol).
• the nephrotoxin can be an illicit drug or a heavy metal.
• the subject has undergone a trauma injury or a crush injury.
• the subject will undergo or has undergone an organ transplant surgery (e.g., a kidney transplant surgery or heart transplant surgery).
• an organ transplant surgery e.g., a kidney transplant surgery or heart transplant surgery.
• the subject will undergo or has undergone a surgery complicated by hypoperfusion.
• the subject will undergo or has undergone cardiothoracic surgery or a vascular surgery.
• the subject will be taking or has taken medication (e.g., an anticholinergic) that interferes with normal emptying of the bladder.
• medication e.g., an anticholinergic
• the subject has benign prostatic hypertrophy or a cancer (e.g., prostate cancer, ovarian cancer, or colorectal cancer).
• a cancer e.g., prostate cancer, ovarian cancer, or colorectal cancer.
• the subject has a kidney stone.
• the subject has an obstructed urinary catheter.
• the subject has taken a drug that causes or leads to crystalluria, a drug that causes or leads to myoglobinuria, or a drug that causes or leads to cystitis.
• FIG. 1 Another embodiments, described herein relate to a method for protecting a kidney from injury in a subject.
• the method involves administering to the subject an effective amount of 15-PGDH inhibitor to protect the subject’s kidney from injury.
• the subject has been or will be exposed to an ischemic or nephrotoxic insult.
• the human subject has been exposed to oxidative damage (e.g., by free radicals such as reactive oxygen or nitrogen species.
• Still further embodiments relate to a method for protecting a human subject's kidney from kidney injury during organ transplantation, such as kidney transplantation.
• the method involves administering to the kidney transplant donor, kidney transplant recipient, and/or transplanted kidney an effective amount of 15-PGDH inhibitor to protect the transplant donor, transplant recipient, and/or transplanted kidney from injury.
• the method further comprises administering to the human subject one or more doses of a 15-PGDH inhibitor before and/or after (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 6,
• 15-PGDH inhibitors potentially used in preventing, treating, or reducing the severity of the renal disorder, disease, and/or injury can be identified using assays in which putative inhibitor compounds are applied to cells expressing 15-PGDH and then the functional effects on 15-PGDH activity are determined. Samples or assays comprising 15-PGDH that are treated with a potential inhibitor are compared to control samples without the inhibitor to examine the extent of effect. Control samples (untreated with modulators) are assigned a relative 15-PGDH activity value of 100%. Inhibition of 15-PGDH is achieved when the 15-PGDH activity value relative to the control is about 80%, optionally 50% or 25%, 10%, 5% or 1%.
• Agents tested as 15-PGDH inhibitors can be any small chemical molecule or compound.
• test compounds will be small chemical molecules, natural products, or peptides.
• the assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically ran in parallel (e.g., in microtiter formats on microtiter plates in robotic assays).
• the 15-PGDH inhibitor can include a compound having the following formula (I): pharmaceutically acceptable salt, tautomer, or solvate thereof; wherein n is 0-2;
• Y 1 , Y 2 , and R 1 are the same or different and are independently hydrogen or a substituted or unsubstituted group selected from C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms, C 6 -C 24 alkaryl, C6-C24 aralkyl, halo, -Si(Ci-C3 alkyl)3, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, C 2 -C 24 alkoxycarbonyl, C 6 -C 20 aryloxycarbonyl, C2-C24 alkylcarbonato, C6-C20 arylcarbona
• X 1 and X 2 are independently N or C, and wherein when X 1 and/or X 2 are N,
• Y 1 and/or Y 2 are absent;
• the 15-PGDH inhibitor can include a compound having the following formula (II): pharmaceutically acceptable salt, tautomer, or solvate thereof; wherein n is 0-2
• X 4 , X 5 , X 6 , and X 7 are independently N or CR C ;
• R 1 , R 6 , R 7 , and R c are the same or different and independently hydrogen or a substituted or unsubstituted group selected from C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C3-C20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms, C6-C24 alkaryl, C6-C24 aralkyl, halo, -Si(Ci-C3 alkyl)3, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C 2 -C 24 alkynyloxy, C 5 -C 20 aryloxy, acyl, acyloxy, C 2 -C 24 alkoxycarbonyl, C 6 -C 20 aryloxycarbonyl, C2-C24 alkylcarbonato, C6-C20 arylcarbona
• Z 1 is O, S, CR a R b or NR a , wherein R a and R b are independently H or a Ci- 8 alkyl, which is linear, branched, or cyclic, and which is unsubstituted or substituted.
• the 15-PGDH inhibitor can include a compound having the following formula (III) or (IV): pharmaceutically acceptable salt, tautomer, or solvate thereof; wherein n is 0-2
• X 6 is independently is N or CR C ;
• R 1 , R 6 , R 7 , and R c are the same or different and independently hydrogen or a substituted or unsubstituted group selected from Ci-C 2 4 alkyl, C 2 -C 2 4 alkenyl, C 2 -C 2 4 alkynyl, C 3 -C 2 o aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms, C6-C 2 4 alkaryl, C 6 -C 24 aralkyl, halo, -Si(Ci-C 3 alkyl) 3 , hydroxyl, sulfhydryl, Ci-C 24 alkoxy, C 2 -C 24 alkenyloxy, C 2 -C 24 alkynyloxy, Cs-CFo aryloxy, acyl, acyloxy, C 2 -C 24 alkoxycarbonyl, C 6 -C 2 o aryloxycarbonyl, C 2 -C 2 4 alkylcarbon
• Z 1 is O, S, CR a R b or NR a , wherein R a and R b are independently H or a Ci- 8 alkyl, which is linear, branched, or cyclic, and which is unsubstituted or substituted.
• R 1 is selected from the group consisting of branched
• R 6 and R 7 can each independently be one of the following: each R 8 , R 9 , R 10 R 11 , R 12 R 13 , R 14 , R 15 , R 16 R 17 , R 18 , R 19 , R 20 R 21 , R 22 R 23 , R 24 R 25
• R 70 R 71 , R 72 , R 73 , and R 74 are the same or different and are independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-C24 alkyl, C2-C24 alkenyl, C2- C24 alkynyl, C3-C20 aryl, heterocycloalkenyl containing from 5-6 ring atoms, (wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C I -C 6 alkyl), NC(0)(C I -C 6 alkyl), O, and S), heteroaryl or heterocyclyl containing from 5-14 ring atoms, (wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C I -C3 alkyl), O, and S),
• R 6 and R 7 can independently be a group that improves aqueous solubility, for example, a phosphate ester (-OPO3H2), a phenyl ring linked to a phosphate ester (-OPO3H2), a phenyl ring substituted with one or more methoxyethoxy groups, or a morpholine, or an aryl or heteroaryl ring substituted with such a group.
• the 15-PGDH inhibitor can include a compound having the following formula (V): pharmaceutically acceptable salt, tatomer, or solvate thereof; wherein n is 0-2
• X 6 is independently is N or CR C
• R 1 , R 6 , R 7 , and R c are the same or different each independently hydrogen or a substituted or unsubstituted group selected from C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C 3 -C 20 aryl, heteroaryl, heterocycloalkenyl containing from 5-6 ring atoms, C 6 -C 24 alkaryl, C6-C24 aralkyl, halo, -Si(Ci-C3 alkyl)3, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alkynyloxy, C5-C20 aryloxy, acyl, acyloxy, C2-C24 alkoxycarbonyl, C6-C20 aryloxycarbonyl, C 2 -C 24 alkylcarbonato, C 6 -C 20 arylcarbonato, carboxy, carb
• R 6 and R 7 can each independently be one of the following: group consisting of hydrogen, substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, heterocycloalkenyl containing from 5-6 ring atoms, (wherein from 1-3 of the ring atoms is independently selected from N, NH, N(CI-C 6 alkyl), NC(0)(Ci- Ce alkyl), O, and S), heteroaryl or heterocyclyl containing from 5-14 ring atoms, (wherein from 1-6 of the ring atoms is independently selected from N, NH, N(CI-C 3 alkyl), O, and S), C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, halo, silyl, hydroxyl, sulfhydryl, C 1 -C 24 alkoxy, C 2
• R 6 and R 7 can independently be a group that improves aqueous solubility, for example, a phosphate ester (-OPO3H2), a phenyl ring linked to a phosphate ester (-OPO3H2), a phenyl ring substituted with one or more methoxyethoxy groups, or a morpholine, or an aryl or heteroaryl ring substituted with such a group.
• the 15-PGDH inhibitor can include a compound having a structure of formula (IA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein: R 1 is alkyl, haloalkyl, cycloalkyl, alkylene-cycloalkyl, alkylene-alkoxy, heterocyclyl, or alkylene-heterocyclyl;
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 6 is heterocyclyl or heteroaryl, each of which is optionally substituted with one or more R 3 ;
• R 7 is alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -C(0)-alkyl, -C(0)0-alkyl, or -C(0)NR 5 -alkyl, each of which is optionally substituted with one or more R 4 ;
• R 3 is oxo, -OH, -O-alkylene-OH, -0-alkylene-N(R 5 ) 2 , -N(R 5 )2, -N(R 5 )(alkylene-OH), -N(R 5 )(alkylene-0-alkyl), alkyl, -alkylene-OH, haloalkyl, cycloalkyl, heterocyclyl, -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(alkylene-OH), -C(0)-alkyl, -C(0)0-alkyl, or -S(0) m - alkyl, wherein the cycloalkyl and the heterocyclyl is each optionally substituted with R 10 ;
• R 4 is oxo, halogen, -CN, -N(R 5 )2, -OH, -O-alkylene-OH, -S(0) m -alkyl, -C(O)- alkyl, -C(0)-cycloalkyl, alkyl, -alkylene-O-alkyl, alkoxy, haloalkyl, cycloalkyl, heterocyclyl, or -alkylene-aryl optionally substituted with R 8 ; each R 5 is independently, H, alkyl, -alkylene-OH optionally substituted with
• R 8 is halogen, alkyl, or alkoxy
• R 9 is H or alkyl, or two R 9 together with the N atom to which they are attached can form a 4- to 7-membered heterocycle, optionally containing an additional heteroatom selected from O, S(0) t , or N;
• R 10 is -OH, halogen, alkyl, or alkoxy; X is N or CH; m is 0, 1, or 2; n is 0, 1, or 2; and t is 0, 1, or 2.
• the 15-PGDH inhibitor can include a compound having a structure of formula (IIA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein: R 1 is alkyl, haloalkyl, cycloalkyl, alkylene-cycloalkyl, alkylene-alkoxy, heterocyclyl, or alkylene-heterocyclyl;
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 6 is heterocyclycl or heteroaryl, each of which is optionally substituted with one or more R 3 ;
• R 7 is alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -C(0)-alkyl, -C(0)0-alkyl, or -C(0)NR 5 -alkyl, each of which is optionally substituted with one or more
• R 3 is oxo, -OH, -0-alkylene-N(R 5 ) 2 , -N(R 5 ) 2 , -N(R 5 )(alkylene-OH), alkyl, haloalkyl, cycloalkyl, heterocyclyl, -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(alkylene-OH), -C(0)-alkyl, -C(0)0-alkyl, or -S(0) m -alkyl;
• R 4 is oxo, halogen, -CN, -N(R 5 ) 2 , -OH, -O-alkylene-OH, -S(0) m -alkyl, -C(O)- alkyl, -C(0)-cycloalkyl, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocyclyl, or -alkylene-aryl optionally substituted with R 8 ; each R 5 is independently, H, alkyl, -alkylene-OH optionally substituted with -OH, -alkylene-NH 2 , -alkylene-N(R 9 ) 2 , -alkylene-O-alkylene-OH, -alkylene-0-alkylene-NH 2 , -C(0)-alkyl, -C(0)0-alkyl, -alkylene-COOH, or -S(0) m -alkyl; or alternatively, two R 5 together with the N
• R 8 is halogen, alkyl, or alkoxy
• R 9 is H or alkyl, or two R 9 together with the N atom to which they are attached can form a 4- to 7-membered heterocycle, optionally containing an additional heteroatom selected from O, S(0) t , or N;
• X is N or CH; m is 0, 1, or 2; n is 0, 1, or 2; and t is 0, 1, or 2.
• R 1 is C1-C6 alkyl, C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, -(C1-C6 alkylene)-(3- to 6-membered cycloalkyl), -(C1-C6 alkylene)-(Ci-C 6 alkoxy), 3- to 6-membered heterocyclyl, or -(C1-C6 alkylene)-(3- to 6-membered heterocyclyl).
• R 1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH 2 ) p -cyclopropyl, -(CH 2 ) P -cyclobutyl, -(CH 2 ) P -cyclopentyl, or -(CH 2 ) P -cyclohexyl; wherein p is 1, 2, or 3.
• R 2 is -NH 2 .
• R 6 is 5- to 6-membered heterocyclycl or 5- to 10- membered heteroaryl, each of which is optionally substituted with one or more R 3 .
• R 6 is 5- to 6-membered heteroaryl optionally substituted with one or more R 3 .
• R 6 is 8- to 10-membered bicyclic heteroaryl optionally substituted with one or more R 3 .
• R 7 is C1-C6 alkyl, C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, 6- to 10-membered aryl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl, -C(0)(Ci-Ce alkyl), -C(0)0(Ci-C 6 alkyl), or -C(0)NR 5 (Ci-C 6 alkyl), each of which is optionally substituted with one or more R 4 .
• R 7 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is C 1 -C 6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, 5- to 10-membered heteroaryl each of which is optionally substituted with one or more R 4 .
• R 3 is -0-(Ci-C6 alkylene)-N(R 5 )2, -N(R 5 )2, -N(R 5 )(CI-C6 alkylene-OH), -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(Ci-C 6 alkylene-OH), -C(0)(Ci-C 6 alkyl), - C(0)0(Ci-C 6 alkyl), or -S(0) m (Ci-C 6 alkyl).
• R 3 is -(C1-C3 alkyl)OH, -NH 2 , -N(C I -C 3 alkyl) 2 , -NHCH2CH2OH, -N(CI-C 3 alkyl)CH2CH 2 OH, N(CH 2 CH 2 OH)2, -NHCH2CH(CH 2 OH)2, -N(C I -C 3 alkyl)CH 2 CH(CH 2 OH) 2 , -NHCH 2 CH 2 OCH 2 CH 2 OH, -NHCH 2 CH 2 OCH 2 CH 2 NH 2 , -NHCH2CH2NH2, -N(CI-C alkyl)CH 2 CH 2 NH2, -NHCH 2 CH 2 NH(CI-C alkyl), -NHCH 2 CH 2 N(CI-C alkyl) 2 , -N(CI-C 3 alkyl)CH 2 CH 2 NH(Ci-C alkyl), -N(CI-C
• R 3 is -NH 2 , -N(C I -C 3 alkyl) 2 , -NHCH 2 CH 2 OH, -N(C I -C 3 alkyl)CH 2 CH 2 OH, N(CH 2 CH 2 OH)2, -NHCH 2 CH(CH 2 OH)2, -N(CI-C 3 alkyl)CH 2 CH(CH 2 OH) 2 , -NHCH 2 CH 2 OCH 2 CH 2 OH, -NHCH 2 CH 2 OCH 2 CH 2 NH 2 , -NHCH2CH2NH2, -N(CI-C 3 alkyl)CH 2 CH 2 NH2, -NHCH 2 CH 2 NH(CI-C3 alkyl), -NHCH 2 CH 2 N(CI-C3 alkyl) 2 , -N(CI-C 3 alkyl)CH 2 CH 2 NH(Ci-C3 alkyl), -N(CI-C 3 alky 1)CH 2 CH 2 N
• R 3 is -NHCH2CH2OH or -N(CH 3 )CH 2 CH 2 OH.
• R 4 is halogen, -CN, -N(R 5 )2, -OH, -0-(Ci-C 6 alkylene)- OH, -S(0) m (Ci-C 6 alkyl), -C(0)(Ci-Ce alkyl), -C(0)-(3- to 6-membered cycloalkyl), Ci-Ce alkyl, C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, or 3- to 6-membered heterocyclyl.
• n is 1.
• the compound has the structure of formula (IIIA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein: R 1 is 3- to 6-membered cycloalkyl, -(C1-C6 alkylene)-(3- to 6-membered cycloalkyl), 3-to 6-membered heterocyclyl, or -(C1-C6 alkylene)-(3- to 6-membered heterocyclyl);
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 6 is heterocyclyl or heteroaryl, each of which is optionally substituted with one or more R 3 ;
• R 7 is alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -C(0)-alkyl, - C(0)0-alkyl, or -C(0)NR 5 -alkyl, each of which is optionally substituted with one or more
• R 3 is oxo, -OH, -0-alkylene-N(R 5 )2, -N(R 5 )2, -N(R 5 )(alkylene-OH), alkyl, haloalkyl, cycloalkyl, heterocyclyl, -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(alkylene-OH), -C(0)-alkyl, - C(0)0-alkyl, or -S(0) m -alkyl,
• R 4 is oxo, halogen, -CN, -N(R 5 )2, -OH, -0-alkylene-OH,-S(0) m -alkyl, -C(O)- alkyl, -C(0)-cycloalkyl, alkyl, haloalkyl, cycloalkyl, heterocyclyl, or - alky lene- aryl optionally substituted with R 8 ; each R 5 is independently, H, alkyl, -alkylene-OH optionally substituted with -OH, -alkylene-NH2, -alkylene-N(R 9 )2, -alkylene-O-alkylene-OH, -alkylene-0-alkylene-NH2, -C(0)-alkyl, -C(0)0-alkyl, -alkylene-COOH, or -S(0) m -alkyl; or alternatively, two R 5 together with the N atom to which they are attached can form a 4- to
• R 8 is halogen, alkyl, or alkoxy
• R 9 is H or alkyl, or two R 9 together with the N atom to which they are attached can form a 4- to 7-membered heterocycle, optionally containing an additional heteroatom selected from O, S(0)t, or N;
• X is N or CH; m is 0, 1, or 2; and t is 0, 1, or 2.
• R 1 is 3- to 5-membered cycloalkyl or -(C1-C6 alkylene)- (3- to 5-membered cycloalkyl).
• R 1 is cyclobutyl
• R 1 is a bicyclic 4- to 6-membered cycloalkyl.
• R 7 is C i - , alkyl, C i - , haloalkyl, 3- to 6-membered cycloalkyl, 6- to 10-membered aryl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl, -C(0)(Ci-C 6 alkyl), -C(0)0(Ci-C 6 alkyl), or -C(0)NR 5 (Ci-C 6 alkyl), each of which is optionally substituted with one or more R 4 .
• R 7 is C1-C4 alkyl, C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, 3- to 6-membered heterocyclyl, or 5- to 10- membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is C1-C3 alkyl, C1-C3 haloalkyl, 3-membered cycloalkyl, phenyl, 4-membered heterocyclyl, or 5- to 6-membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is C1-C3 haloalkyl, 3-membered cycloalkyl, phenyl, 4-membered heterocyclyl, or 5- to 6-membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is -CF3, isopropyl, cyclopropyl, phenyl, pyridyl, pyrazole, or triazole, each of which is optionally substituted with one or more R 4 .
• R 7 is -CF3, cyclopropyl, phenyl, pyridyl, pyrazole, or triazole, each of which is optionally substituted with one or more R 4 .
• R 3 is -0-(Ci-C6 alkylene)-N(R 5 )2, -N(R 5 )2, -N(R 5 )(CI-C6 alkylene-OH), -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(Ci-C 6 alkylene-OH), -C(0)(Ci-C 6 alkyl), -C(0)0(Ci-C 6 alkyl), or -S(0) m (Ci-C 6 alkyl).
• R 3 is -NH 2 , -N(C I -C 3 alkyl) 2 , -NHCH 2 CH 2 OH, -N(C I -C 3 alkyl)CH2CH 2 OH, N(CH 2 CH 2 OH)2, -NHCH2CH(CH 2 OH)2, -N(CI-C 3 alkyl)CH 2 CH(CH 2 OH) 2 , -NHCH 2 CH 2 OCH 2 CH 2 OH, -NHCH 2 CH 2 OCH 2 CH 2 NH 2 , -NHCH2CH2NH2, -N(CI-C 3 alkyl)CH 2 CH2NH2, -NHCH 2 CH2NH(CI-C 3 alkyl), -NHCH 2 CH 2 N(CI-C alkyl) 2 , -N(CI-C alkyl)CH 2 CH2NH(Ci-C alkyl), -N(CI-C alky 1)CH 2 CH 2 N (C 1 -C 3
• R 3 is -NHCH 2 CH 2 OH or -N(CH 3 )CH 2 CH 2 OH.
• substituents at the R 7 position could be modified to improve hERG activity, including hERG inhibition (IC50), blockade, and efflux ratio.
• IC50 hERG inhibition
• certain 6- to 10-membered aryls e.g., optionally substituted phenyl
• 5- to 10-membered heteroaryls e.g., optionally substituted pyridyls, pyrazoles, and triazoles
• C1-C6 haloalkyls e.g., -CF 3
• the compound has the structure of formula (IVA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein: R 1 is cycloalkyl, alkylene-cycloalkyl, alkylene-alkoxy, heterocyclyl, or alkylene-heterocyclyl;
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 6 is heterocyclyl or heteroaryl, each of which is optionally substituted with one or more R 3 ;
• R 7 is C1-C6 haloalkyl, aryl or heteroaryl, each of which is optionally substituted with one or more R 4 ;
• R 3 is oxo, -OH, -0-alkylene-N(R 5 ) 2 , -N(R 5 )2, -N(R 5 )(alkylene-OH), alkyl, haloalkyl, cycloalkyl, heterocyclyl, -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(alkylene-OH), -C(0)-alkyl, - C(0)0-alkyl, or -S(0) m -alkyl; each R 5 is independently, H, alkyl, -alkylene-OH optionally substituted with -OH, -alkylene-NH2, -alkylene-N(R 9 )2, -alkylene-O-alkylene-OH, -alkylene-0-alkylene-NH2, -C(0)-alkyl, -alkylene-COOH, -C(0)0-alkyl, or -S(0) m -alkyl; or alternative
• R 4 is halogen, alkyl, or alkoxy
• X is N or CH; and m is 0, 1, or 2.
• R 7 is -CF 3 , pyridyl, pyrazole, phenyl, or triazole, each of which is optionally substituted with R 4 .
• R 7 is -CF 3 , pyridyl, fluorophenyl, or a triazole optionally substitued with halogen or methyl.
• R 7 is -CF 3.
• R 7 is F
• R 6 is 8- to 10-membered bicyclic heteroaryl optionally substituted with one or more R 3 .
• the compound has the structure of formula (VA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein:
• R 1 is cycloalkyl, -alkylene-cycloalkyl, -alkylene-alkoxy, heterocyclyl, or -alkylene-heterocyclyl;
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 6 is heterocyclyl or heteroaryl, each of which is optionally substituted with one or more R 3 ;
• R 7 is 3- to 6-membered cycloalkyl, optionally substituted with one or more R 4 ;
• R 3 is oxo, -OH, -0-alkylene-N(R 5 ) 2 , -N(R 5 ) 2 , -N(R 5 )(alkylene-OH), alkyl, haloalkyl, cycloalkyl, heterocyclyl, -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(alkylene-OH), -C(0)-alkyl, -C(0)0-alkyl, or -S(0) m -alkyl;
• R 4 is halogen, -CN, -NH 2 , -OH, or C1-C3 alkyl; each R 5 is independently, H, alkyl, -alkylene-OH optionally substituted with -OH, -alkylene-Nfh, -alkylene-N(R 9 )2, -alkylene-O-alkylene-OH, -alkylene-0-alkylene-NH2, -C(0)-alkyl, -alkylene-COOH, -C(0)0-alkyl, or -S(0) m -alkyl; or alternative, two R 5 together with the N atom to which they are attached can form a 4- to 7-membered heterocycle, optionally containing an additional heteroatom selected from O, S, or N, and wherein the heterocycle is optionally substituted with R 8 ;
• R 8 is halogen, alkyl, or alkoxy
• X is N or CH; m is 0, 1, or 2.
• R 7 is cyclopropyl
• R 1 is 3- to 6-membered cycloalkyl, -(C1-C6 alkylene)-(3- to 6-membered cycloalkyl), -(C 1 -C 6 alkylene)-(Ci-C 6 alkoxy), 3- to 6-membered heterocyclyl, or -(C1-C6 alkylene)-(3- to 6-membered heterocyclyl).
• R 1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH 2 ) p -cyclopropyl, -(CH 2 ) P -cyclobutyl, -(CH 2 ) P -cyclopentyl, or -(CH 2 ) P -cyclohexyl; wherein p is 1, 2, or 3.
• R 3 is -0-(Ci-C6 alkylene)-N(R 5 )2, -N(R 5 )2, -N(R 5 )(CI-C6 alkylene-OH), -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(Ci-C 6 alkylene-OH), -C(0)(Ci-C 6 alkyl), -C(0)0(Ci-C 6 alkyl), or -S(0) m (Ci-C 6 alkyl).
• R 3 is -NH 2 , -N(C I -C 3 alkyl) 2 , -NHCH 2 CH 2 OH, -N(C I -C 3 alkyl)CH 2 CH 2 OH, N(CH 2 CH 2 OH)2, -NHCH 2 CH(CH 2 OH)2, -N(CI-C 3 alkyl)CH2CH(CH 2 OH)2, -NHCH2CH2OCH2CH2OH, -NHCH2CH2OCH2CH2NH2, -NHCH2CH2NH2, -N(CI-C 3 alkyl)CH 2 CH 2 NH2, -NHCH 2 CH 2 NH(CI-C3 alkyl), -NHCH 2 CH 2 N(CI-C3 alkyl) 2 , -N(CI-C 3 alkyl)CH 2 CH 2 NH(Ci-C3 alkyl), -N(CI-C 3 alkyl)CH 2 CH2N(Ci-C3 alkyl), -N
• R 3 is -NHCH 2 CH 2 OH or -N(CH 3 )CH 2 CH 2 OH.
• the compound has the structure of formula (VIA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein:
• R 1 is cycloalkyl, -alkylene-cycloalkyl, -alkylene-alkoxy, heterocyclyl, or -alkylene-heterocyclyl;
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 6 is heterocyclyl or heteroaryl, each of which is substituted with one or more
• R 7 is haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -C(0)-alkyl, - C(0)0-alkyl, or -C(0)NR 5 -alkyl, each of which is optionally substituted with one or more
• R 3 is -0-(Ci-Ce alkylene)-N(R 5 ) 2 , -N(R 5 ) 2 , -N(R 5 )(CI-C 6 alkylene-OH), - C(0)N(R 5 ) 2 , -C(0)N(R 5 )(CI-C 6 alkylene-OH), -C(0)(Ci-C 6 alkyl), -C(0)0(Ci-C 6 alkyl), or - S(0) m (Ci-C 6 alkyl);
• R 4 is oxo, halogen, -CN, -N(R 5 ) 2 , -OH, -O-alkylene-OH, -S(0) m -alkyl, -C(O)- alkyl, -C(0)-cycloalkyl, alkyl, haloalkyl, cycloalkyl, heterocyclyl, or - alky lene- aryl optionally substituted with R 8 ; each R 5 is independently H, C1-C6 alkyl, -(C1-C6 alkylene)-OH optionally substituted with -OH, -alkylene-NH 2 , -alkylene-N(R 9 ) 2 , -alkylene-O-alkylene-OH, -alkylene- 0-alkylene-NH 2 , -C(0)(Ci-Ce alkyl), -C(0)0(Ci-Ce alkyl), alkylene-COOH, or -S(0)
• R 8 is halogen, alkyl, or alkoxy
• X is N or CH; m is 0, 1, or 2.
• R 3 is -0-(Ci-C 6 alkylene)-N(R 5 ) 2 , -N(R 5 ) 2 or -N(R 5 )(C I - Ce alkylene-OH).
• R 5 is H, Ci-Ce alkyl, -(C1-C6 alkylene)-OH, or -S(0) 2 (Ci- C 3 alkyl).
• R 3 is -NH2, -N(C I -C 3 alkyl)2, -NHCH2CH2OH, -N(C I -C 3 alkyl)CH 2 CH 2 OH, N(CH 2 CH 2 OH)2, -NHCH 2 CH(CH 2 OH)2, -N(CI-C 3 alkyl)CH 2 CH(CH 2 OH)2, -NHCH2CH2OCH2CH2OH, -NHCH2CH2OCH2CH2NH2, -NHCH2CH2NH2, -N(C I -C alkyl)CH 2 CH 2 NH2, -NHCH 2 CH 2 NH(C I -C alkyl), -NHCH 2 CH 2 N(CI-C alkyl) 2 , -N(CI-C alkyl)CH 2 CH2NH(Ci-C alkyl), -N(CI-C alky 1)CH 2 CH 2 N (C 1 -C alkyl) 2 ,
• R 3 is -NHCH2CH2OH or -N(CH )CH 2 CH 2 OH.
• R 3 is -NHCH2CH2OH.
• R 6 is 5- to 6-membered heterocyclyl or 5- to 10- membered heteroaryl, each of which is optionally substituted with one or more R 3 .
• R 6 is 5- to 6-membered heteroaryl optionally substituted with one or more R 3 .
• R 6 is furan, thiophene, pyrrole, thiazole, isothiazole, oxazole, isooxazole, pyrazole, imidazole, triazole, pyridine, pyrimidine, pyridazine, or pyrazine, each optionally substituted with one or more R 3 .
• R 6 is thiazole, imidazole, oxazole, pyridine, or pyrimidine.
• R 6 is 8- to 10-membered bicyclic heteroaryl optionally substituted with one or more R 3 .
• R 6 is 5- to 6-membered heterocyclyl, optionally substituted with one or more R 3 , selected from morpholine, pyridine-one, or piperidine.
• R 7 is Ci-C 3 haloalkyl, 3-membered cycloalkyl, phenyl, 4-membered heterocyclyl, or 5- to 6-membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is -CF 3 , cyclopropyl, phenyl, pyrzole, pyridyl, or triazole, each of which is optionally substituted with one or more R 4 .
• the compound has the structure of formula (VIIA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein:
• R 1 is cycloalkyl, alkylene-cycloalkyl, alkylene-alkoxy, heterocyclyl, or alkylene-heterocyclyl;
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 6 is fused bicyclic heterocyclyl or fused bicyclic heteroaryl, each of which is optionally substituted with one or more R 3 ;
• R 7 is alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -C(0)-alkyl, -C(0)0-alkyl, or -C(0)NR 5 -alkyl, each of which is optionally substituted with one or more
• R 3 is oxo, -OH, -0-alkylene-N(R 5 ) 2 , -N(R 5 ) 2 , -N(R 5 )(alkylene-OH), alkyl, haloalkyl, cycloalkyl, heterocyclyl, -C(0)N(R 5 ) 2 , -C(0)-alkyl, -C(0)0-alkyl, or -S(0) m -alkyl;
• R 4 is oxo, halogen, -CN, -N(R 5 ) 2 , -OH, -O-alkylene-OH, -S(0) m -alkyl, -C(O)- alkyl, -C(0)-cycloalkyl, alkyl, haloalkyl, cycloalkyl, heterocyclyl, or - alky lene- aryl optionally substituted with R 8 ; each R 5 is independently, H, alkyl, -alkylene-OH optionally substituted with -OH, -alkylene-O-alkylene-OH, -alkylene-0-alkylene-NH 2 , -C(0)-alkyl, -C(0)0-alkyl, or - S(0) m -alkyl; or alternatively, two R 5 together with the N atom to which they are attached can form a 4- to 7-membered heterocycle, optionally containing an additional heteroatom selected from O, S, or N
• R 8 is halogen, alkyl, or alkoxy
• X is N or CH; and m is 0, 1, or 2.
• R 6 is 8- to 10-membered fused bicyclic heteroaryl, each of which is optionally substituted with one or more R 3 .
• R 7 is C1-C6 alkyl, C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, 6- to 10-membered aryl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl, -C(0)(Ci-C 6 alkyl), -C(0)0(Ci-C 6 alkyl), or -C(0)NR 5 (Ci-C 6 alkyl), each of which is optionally substituted with one or more R 4 .
• R 7 is C1-C4 alkyl, C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, 3- to 6-membered heterocyclyl, or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, 3- to 6-membered heterocyclyl, or 5- to 10- membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is C 1 -C 3 alkyl, C 1 -C 6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, 3- to 6-membered heterocyclyl, or 5- to 6-membered heteroaryl, each of which is optionally substituted with one or more R 4 .
• R 7 is C 1 -C 3 alkyl, C 1 -C 6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, pyrazole, pyridyl, or triazole, each of which is optionally substituted with one or more R 4 .
• R 7 is C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, phenyl, pyrazole, pyridyl, or triazole, each of which is optionally substituted with one or more R 4 .
• R 7 is -CF 3 , isopropyl, cyclopropyl, phenyl, pyridyl, or triazole, each of which is optionally substituted with one or more R 4 .
• R 7 is -CF 3 , cyclopropyl, phenyl, pyridyl, or triazole, each of which is optionally substituted with one or more R 4 .
• R 1 is C1-C6 alkyl, C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, -(C1-C6 alkylene)-(3- to 6-membered cycloalkyl), -(C1-C6 alkylene)-(Ci-C6 alkoxy), 3- to 6-membered heterocyclyl, or -(C1-C6 alkylene)-(3- to 6-membered heterocyclyl).
• R 1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH2) p -cyclopropyl, -(CH2) P -cyclobutyl, -(CH2) P -cyclopentyl, or -(CH2) P -cyclohexyl; wherein p is 1, 2, or 3.
• R 3 is -0-(Ci-C6 alkylene)-N(R 5 )2, -N(R 5 )2, -N(R 5 )(CI-C6 alkylene-OH), -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(Ci-C 6 alkylene-OH), -C(0)(Ci-C 6 alkyl), -C(0)0(Ci-C 6 alkyl), or -S(0) m (Ci-C 6 alkyl).
• R 3 is -NH 2 , -N(C I -C 3 alkyl) 2 , -NHCH2CH2OH, -N(C I -C 3 alkyl)CH 2 CH 2 OH, N(CH 2 CH 2 OH)2, -NHCH 2 CH(CH 2 OH)2, -N(CI-C 3 alkyl)CH 2 CH(CH 2 OH)2, -NHCH2CH2OCH2CH2OH, -NHCH2CH2OCH2CH2NH2, -NHCH2CH2NH2, -N(CI-C 3 alkyl)CH 2 CH 2 NH2, -NHCH 2 CH 2 NH(CI-C3 alkyl), -NHCH 2 CH 2 N(CI-C3 alkyl) 2 , -N(CI-C 3 alkyl)CH 2 CH 2 NH(Ci-C3 alkyl), -N(CI-C 3 alky 1)CH 2 CH 2 N (C 1 -C 3
• R 3 is -NHCH2CH2OH or -N(CH 3 )CH 2 CH 2 OH.
• R 4 is halogen, -CN, -N(R 5 )2, -OH, -0-(Ci-C 6 alkylene)-
• the compound has the structure of formula (VIIIA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein: R 1 is cyclobutyl or -(C1-C4 alkylene)-(Ci-C3 alkoxy);
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 6 is heterocyclyl or heteroaryl, each of which is optionally substituted with one or more R 3 ;
• R 3 is oxo, -OH, -O-alkylene-OH, -0-alkylene-N(R 5 )2, -N(R 5 )2, - N(R 5 )(alkylene-OH), -N(R 5 )(alkylene-0-alkyl), alkyl, -alkylene-OH, haloalkyl, cycloalkyl, heterocyclyl, -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(alkylene-OH), -C(0)-alkyl, -C(0)0-alkyl, or -S(0) m - alkyl, wherein the cycloalkyl and the heterocyclyl is each optionally substituted with R 10 ;
• R 4 is C 1 -C 3 alkyl; each R 5 is independently, H, alkyl, -alkylene-OH optionally substituted with -OH, -alkylene-NH2, -alkylene-N(R 9 )2, -alkylene-O-alkylene-OH, -alkylene-0-alkylene-NH2, -C(0)-alkyl, -C(0)0-alkyl, -alkylene-COOH, or -S(0) m -alkyl; or alternatively, two R 5 together with the N atom to which they are attached can form a 4- to 7-membered heterocycle, optionally containing an additional heteroatom selected from O, S, or N, and wherein the heterocycle is optionally substituted with R 8 ;
• R 8 is halogen, alkyl, or alkoxy
• R 9 is H or alkyl, or two R 9 together with the N atom to which they are attached can form a 4- to 7-membered heterocycle, optionally containing an additional heteroatom selected from O, S(0)t, or N;
• R 10 is -OH, halogen, alkyl, or alkoxy
• X is N or CH; m is 0, 1, or 2; p is 0 or 1 ; and t is 0, 1, or 2.
• R 2 is -NH2.
• R 6 is 5- to 6-membered heterocyclycl or 5- to 10-membered heteroaryl, each of which is optionally substituted with one or more R 3 .
• R 6 is 5- to 6-membered heteroaryl optionally substituted with one or more R 3 .
• R 6 is 8- to 10-membered bicyclic heteroaryl optionally substituted with one or more R 3 .
• R 3 is -0-(Ci-C6 alkylene)-N(R 5 )2, -N(R 5 )2, -N(R 5 )(CI-C6 alkylene-OH), -C(0)N(R 5 ) 2 , -C(0)N(R 5 )(Ci-C 6 alkylene-OH), -C(0)(Ci-Ce alkyl), -C(0)0(Ci-C 6 alkyl), or -S(0) m (Ci-C 6 alkyl).
• R 3 is -(C 1 -C 3 alkyl)OH, -NH2, -N(C I -C3 alkyl)2, -NHCH2CH2OH, -N(CI-C 3 alkyl)CH 2 CH 2 OH, N(CH 2 CH 2 OH)2, -NHCH2CH(CH 2 OH)2, -N(C I -C 3 alkyl)CH 2 CH(CH 2 OH)2, -NHCH2CH2OCH2CH2OH, -NHCH2CH2OCH2CH2NH2, -NHCH2CH2NH2, -N(CI-C alkyl)CH 2 CH 2 NH2, -NHCH 2 CH 2 NH(CI-C alkyl), -NHCH 2 CH 2 N(CI-C alkyl) 2 , -N(CI-C 3 alkyl)CH 2 CH 2 NH(Ci-C alkyl), -N(CI-C 3 alky 1)CH 2 CH 2 N
• R 3 is -NHCH2CH2OH or -N(CH 3 )CH 2 CH 2 OH.
• R 4 is halogen, -CN, -N(R 5 )2, -OH, -0-(Ci-C 6 alkylene)- OH, -S(0) m (Ci-C 6 alkyl), -C(0)(Ci-C 6 alkyl), -C(0)-(3- to 6-membered cycloalkyl), Ci-C 6 alkyl, C1-C6 haloalkyl, 3- to 6-membered cycloalkyl, or 3- to 6-membered heterocyclyl.
• n is 1.
• the compound has the structure of formula (IXA): or a pharmaceutically acceptable salt, tautomer, or solvate thereof, wherein: R 1 is cyclobutyl or -(C 1 -C 4 alkylene)-(Ci-C 3 alkoxy);
• R 2 is -NH 2 , CN, or -NHC(0)alkyl
• R 7 is -CF 3 , isopropyl, cyclopropyl, cyclobutyl, , each of which is optionally substituted with one or more R 4 ;
• R 3 is -NH 2 , -NH(C I -C alkyl), -NH(C I -C 4 alkylene)-OH, or C 1 -C 3 alkyl;
• R 4 is C 1 -C 3 alkyl; and X is N or CH.
• R 1 is cyclobutyl. In some embodiments of Formula (IXA), R 1 -(C 1 -C 4 alkylene)-(Ci-C3 alkoxy). In some embodiments of Formula (IXA), the R 1 -(C 1 -C 4 alkylene)-(Ci-C 3 alkoxy) is -(C 2 -C 3 alkylene)-(Ci alkoxy). [00208] In some embodiments of Formula (IXA), R 2 is -NH 2 . [00209] In some embodiments of Formula (IXA), R 6 is
• R 3 is -NFF. In some embodiments of Formula (IXA), R 3 is -NH(C I -C3 alkyl). In some embodiments of Formula (IXA), R 3 is - NH(C I -C4 alkylene)-OH (e.g., -NH(C2-C4 alkylene)-OH). In some embodiments of Formula (IXA), R 3 is C1-C3 alkyl (e.g., methyl or ethyl).
• R 7 is -CF3, isopropyl, cyclopropyl, or cyclobutyl. In some embodiments, of Formula (IXA), R 7 is isopropyl. In some embodiments of Formula (VII), R 7 is , each of which is optionally substituted with one or more R 4 . In some embodiments, each R 4 is idependently selected from methyl or ethyl.
• X is -CH.
• the 15-PGDH inhibitor can include a compound selected from:
• the 15-PGDH inhibitor can include compound having at least one of the formulas (IB) or (IIB), or a pharmaceutically acceptable salt, tautomer, or solvate thereof: wherein X 1 is N or CR 4 ;
• X 3 is CR 8 , the compound forming a polycyclic heteroaryl with 10 ring atoms, or absent, the compound forming a polycyclic heteroaryl with 9 ring atoms;
• X 4 is N, NH, or CR 7 ;
• R 1 , R 2 , R 3 , R 4 R 9 , R 10 , and R 16 are the same or different and are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heterocycloalkenyl containing from 5-7 ring atoms, (wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C I -C 6 alkyl), NC(O) (C 1 -C 6 alkyl), O, and S), heteroaryl or heterocyclyl containing from 5-14 ring atoms, (wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C I -C 3 alkyl), O, and S), C6-C24 alkaryl, C6-C24 aralkyl, halo, silyl, hydroxy
• R 7 and R 8 are same or different and are each independently selected from the group consisting of H, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted cycloalkyl, and a substituted or unsubstituted heterocyclyl, and at least one of R 7 or R 8 is not H.
• At least one of R 2 or R 3 is not H, and at least one of R 9 or R 10 is not H.
• R 1 , R 2 , R 3 , R 5 , R 6 , and R 14 are the same or different and are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, heterocycloalkenyl containing from 5-7 ring atoms, (wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C I -C 6 alkyl), NC(O) (C 1 -C 6 alkyl), O, and S), heteroaryl or heterocyclyl containing from 5-14 ring atoms, (wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C I -C 3 alkyl), O, and S), C 6 -C 24 alkaryl, C 6 -C 24 aralkyl, halo, silyl, hydroxyl, sul
• Y is independently H, aryl or alkyl
• R 7 and R 8 are same or different and are each independently selected from the group consisting of H, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted cycloalkyl, and a substituted or unsubstituted heterocyclyl, and at least one of R 7 or R 8 is not H;
• R 9 , R 10 , R 11 , R 12 , R 13 , andR 15 are the same or different and are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 24 alkyl, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, C 3 -C 20 aryl, heterocycloalkenyl containing from 5-7 ring atoms, (wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C I -C 6 alkyl), NC(O) (C 1 -C 6 alkyl), O, and S), heteroaryl or heterocyclyl containing from 5-14 ring atoms, (wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C I -C 3 alkyl), O, and S), C6-C24 alkaryl, C6-C24 aralkyl, halo, silyl, hydroxyl,
• Examples of 15-PGDH inhibitors having formulas (IB), (IBa), (IBb), (IBc), (IBd), (IBe), (IIB), (IIBa), (IIBb), (IIBc), (IIBd), (IBe), or (IIBf) can include the following compounds:
• 15-PGDH inhibitors include compounds described in WO2018/145080, which is incorporated by reference in its entirety.
• the 15-PGDH inhibitor can be selected that can ia) at 2.5 mM concentration, stimulate a Vaco503 reporter cell line expressing a 15-PGDH lucif erase fusion construct to a luciferase output level of greater than 70 (using a scale on which a value of 100 indicates a doubling of reporter output over baseline); iia) at 2.5 pM concentration stimulate a V9m reporter cell line expressing a 15-PGDH luciferase fusion construct to a luciferase output level of greater than 75; iiia) at 7.5 m M concentration stimulate a LS174T reporter cell line expressing a 15-PGDH luciferase fusion construct to a luciferase output level of greater than 70; and iva) at 7.5 mM concentration, does not activate a negative control V9m cell line expressing TK-renilla luciferase reporter to a level greater than 20; and va) inhibit
• the 15-PGDH inhibitor can ib) at 2.5 mM concentration, stimulate a Vaco503 reporter cell line expressing a 15-PGDH luciferase fusion construct to increase luciferase output; iib) at 2.5 mM concentration stimulate a V9m reporter cell line expressing a 15-PGDH luciferase fusion construct to increase luciferase output; iiib) at 7.5 mM concentration stimulate a LS174T reporter cell line expressing a 15-PGDH luciferase fusion construct to increase luciferase output; ivb) at 7.5 mM concentration, does not activate a negative control V9m cell line expressing TK-renilla luciferase reporter to a luciferase level greater than 20% above background; and vb) inhibits the enzymatic activity of recombinant 15-PGDH protein at an IC50 of less than 1 mM.
• the 15-PGDH inhibitor can inhibit the enzymatic activity of recombinant 15-PGDH at an IC50 of less than 1 mM, or preferably at an IC50 of less than 250 nM, or more preferably at an IC50 of less than 50 nM, or more preferably at an IC50 of less than 10 nM, or more preferably at an IC50 of less than 5 nM at a recombinant 15-PGDH concentration of about 5 nM to about 10 nM.
• 15-PGDH inhibitors can be used in the methods described herein.
• These other 15-PGDH inhibitors can include known 15-PGDH inhibitors including, for example, tetrazole compounds of formulas (I) and (II), 2-alkylideneaminooxyacetamide compounds of formula (I), heterocyclic compounds of formulas (VI) and (VII), and pyrazole compounds of formula (III) described in U.S. Patent Application Publication No. 2006/0034786 and U.S. Patent No. 7,705,041; benzylidene-1,3- thiazolidine compounds of formula (I) described in U.S. Patent Application Publication No.
• 2007/0071699 phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds described in U.S. Patent Application Publication No. 2007/0078175; thiazolidenedione derivatives described in U.S. Patent Application Publication No. 2011/0269954; phenylfuran, phenylthiophene, or phenylpyrrazole compounds described in U.S. Patent No. 7,294,641, 5-(3,5-disubstituted phenylazo)-2-hydroxybenzene-acetic acids and salts and lactones described in U.S. Patent No. 4,725,676, and azo compounds described in U.S. Patent No. 4,889,846.
• 15-PGDH inhibitors are described in the following publications: Seo SY et al. Effect of 15-hydroxyprostaglandin dehydrogenase inhibitor on wound healing. Prostaglandins Leukot Essent Fatty Acids. 2015;97:35-41. doi:
• PubMed PMID 25899574; Piao YL et al. Wound healing effects of new 15-hydroxyprostaglandin dehydrogenase inhibitors. Prostaglandins Leukot Essent Fatty Acids. 2014;91(6):325-32. doi: 10.1016/j.plefa.2014.09.011. PubMed PMID: 25458900; Choi D et al. Control of the intracellular levels of prostaglandin E(2) through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing. Bioorg Med Chem. 2013;21(15):4477-84. doi: 10.1016/j.bmc.2013.05.049.
• the 15-PGDH inhibitors described herein can be used to treat, prevent, or reduce the symptoms or severity of the renal disorder, disease, and/or injury in a subject (e.g., a human subject) in need thereof.
• the 15-PGDH inhibitors are also useful in preventing the development of chronic kidney disease in a subject in need thereof.
• the 15-PGDH inhibitors are useful in preventing the development of chronic kidney disease in a subject in need thereof following an insult that can cause or causes acute kidney injury.
• the 15-PGDH inhibitors described herein can be used in methods for protecting a kidney from acute or chronic kidney injury in a subject in need thereof.
• the 15-PGDH inhibitors described herein can be used in methods for treating patients with renal insufficiency or renal failure, attributable at least in part to use of a drug or chemical.
• Acute kidney injury is commonly divided into two major categories based on the type of insult.
• the first category is ischemic acute kidney injury (alternatively referred to as kidney hypoperfusion) and the second category is nephrotoxic acute kidney injury.
• the former results from impaired blood flow (kidney hypoperfusion) and oxygen delivery to the kidney; whereas, the latter results from a toxic insult to the kidney.
• Both of these categories of insults can lead to a secondary condition called acute tubular necrosis (ATN).
• ATN acute tubular necrosis
• Intravascular volume depletion can be caused by hemorrhage (e.g., following surgery, postpartum, or trauma); gastrointestinal loss (e.g., from diarrhea, vomiting, nasogastric loss); renal losses (e.g., caused by diuretics, osmotic diuresis, diabetes insipidus); skin and mucous membrane losses (e.g., burns, hyperthermia); nephrotic syndrome; cirrhosis; or capillary leak.
• hemorrhage e.g., following surgery, postpartum, or trauma
• gastrointestinal loss e.g., from diarrhea, vomiting, nasogastric loss
• renal losses e.g., caused by diuretics, osmotic diuresis, diabetes insipidus
• skin and mucous membrane losses e.g., burns, hyperthermia
• Reduced cardiac output can be due to cardiogenic shock, pericardial disease (e.g., restrictive, constrictive, tamponade), congestive heart failure, valvular heart disease, pulmonary disease (e.g., pulmonary hypertension, pulmonary embolism), or sepsis.
• pericardial disease e.g., restrictive, constrictive, tamponade
• congestive heart failure e.g., congestive heart failure
• valvular heart disease e.g., pulmonary hypertension, pulmonary embolism
• Sepsis e.g., pulmonary hypertension, pulmonary embolism
• Systemic vasodilation can be the result of cirrhosis, anaphylaxis, or sepsis.
• renal vasoconstriction can be caused by early sepsis, hepatorenal syndrome, acute hypercalcemia, drug-related (e.g., norepinephrine, vasopressin, nonsteroidal anti inflammatory drugs, angiotensin-converting enzyme inhibitors, calcineurin inhibitors), or use of a radiocontrast agent.
• drug-related e.g., norepinephrine, vasopressin, nonsteroidal anti inflammatory drugs, angiotensin-converting enzyme inhibitors, calcineurin inhibitors
• the 15-PGDH inhibitors described herein can be used to treat or reduce the symptoms or severity of acute kidney injury or any other kidney injury caused by any of the above mentioned causes of ischemic acute kidney injury.
• the 15- PGDH inhibitors thereof described herein can be used to prevent the development of acute kidney injury or any other kidney injury following exposure to the above-mentioned causes of ischemic acute kidney injury.
• Nephrotoxic acute kidney injury is often associated with exposure to a nephrotoxin such as a nephrotoxic drug.
• nephrotoxic drugs include an antibiotic (e.g., aminoglycosides such as gentamicin), a chemotherapeutic agent (e.g., cis -platinum), a calcineurin inhibitor (e.g., tacrolimus, cyclosporine), cephalosporins such as cephaloridine, cyclosporin, pesticides (e.g., paraquat), environmental contaminants (e.g., trichloroethylene, dichloroacetylene), amphotericin B, puromcyin, aminonucleoside (PAN), a radiographic contrast agent (e.g., acetrizoate, diatrizoate, iodamide, ioglicate, iothalamate, ioxithalamate, metrizoate, metrizamide
• a nephrotoxin can be, for example, a trauma injury, a crush injury, an illicit drug, analgesic abuse, a gunshot wound, or a heavy metal.
• the 15- PGDH inhibitors described herein can be used to treat or reduce the symptoms or severity of acute kidney injury or any other kidney injury caused by any of the above mentioned causes of nephrotoxic acute kidney injury.
• the 15-PGDH inhibitors described herein can be used to prevent the development of acute kidney injury or any other kidney injury following exposure to the above mentioned causes of nephrotoxic acute kidney injury.
• the 15-PGDH inhibitors described herein can be used to prevent the development of ATN following exposure to an insult such as ischemia or nephro toxins/nephrotoxic drugs. In certain embodiments, the 15-PGDH inhibitors described herein can be used to treat or reduce the symptoms or severity of ATN following ischemia or exposure to nephro toxins/nephrotoxic drugs.
• the 15-PGDH inhibitors described herein can be used to prevent a drop in glomerular filtration following ischemia or exposure to nephrotoxins/nephrotoxic drugs. In some embodiments, the 15-PGDH inhibitors can be used to prevent tubular epithelial injury and/or necrosis following ischemia or exposure to nephrotoxins/nephrotoxic drugs. In some embodiments, the 15-PGDH inhibitors can be used to decrease the microvascular permeability, improve vascular tone, and/or reduce inflammation of endothelial cells. In other embodiments, the 15-PGDH inhibitors described herein can be used to restore blood flow in the kidney following ischemia or exposure to nephro toxins/nephrotoxic drugs. In further embodiments, the 15-PGDH inhibitors described herein can be used to prevent chronic renal failure.
• the 15-PGDH inhibitors described herein can also be used to treat or prevent acute kidney injury resulting from surgery complicated by hypoperfusion.
• the surgery is one of cardiac surgery, major vascular surgery, major trauma, or surgery associated with treating a gunshot wound.
• the cardiac surgery is coronary artery bypass grafting (CABG).
• CABG coronary artery bypass grafting
• the cardiac surgery is valve surgery.
• the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury following organ transplantation such as kidney transplantation or heart transplantation.
• the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury following reduced effective arterial volume and kidney hypoperfusion.
• the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury in a subject who is taking medication (e.g., an anticholinergic) that interferes with normal emptying of the bladder. In certain embodiments, the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury in a subject who has an obstructed urinary catheter. In some embodiments, the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury in a subject who is taking a drug that causes crystalluria. In some embodiments, the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury in a subject who is taking a drug that causes or leads to myoglobinuria. In some embodiments, the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury in a subject who is taking a drug that causes or leads to cystitis.
• medication e.g., an anticholinergic
• the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury in a subject who has benign prostatic hypertrophy or prostate cancer. [00237] In some embodiments, the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury in a subject who has a kidney stone.
• the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury in a subject who has an abdominal malignancy (e.g., ovarian cancer, colorectal cancer).
• abdominal malignancy e.g., ovarian cancer, colorectal cancer.
• the 15-PGDH inhibitors described herein can be used to treat or prevent acute kidney injury, wherein sepsis does not cause or result in the acute kidney injury.
• Acute kidney injury typically occurs within hours to days following the original insult (e.g., ischemia or nephrotoxin insult).
• 15-PGDH inhibitors described herein can be administered before the insult, or within an hour to 30 days (e.g., 0.5 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 15 days, 20 days, 25 days, 28 days, or 30 days) after the insult (e.g., a surgery or nephrotoxin insult described herein).
• a subject can be determined to have, or have the risk of developing, acute kidney injury based on, e.g., the Risk Injury Failure Loss ESRD (RIFLE) criteria or the Acute Kidney Injury Network criteria (Bagshaw et ak, Nephrol. Dial. Transplant., 23 (5):1569-1574 (2008); Lopes et ak, Clin. Kidney L, 6(1):8-14 (2013)).
• REFLE Risk Injury Failure Loss ESRD
• the methods of this disclosure involve determining measuring the levels of one or more of: serum, plasma or urine creatinine or blood urea nitrogen (BUN); measuring the levels of serum or urine neutrophil gelatinase-associated lipocalin (NGAL), serum or urine interleukin- 18 (IL-18), serum or urine cystatin C, or urine KIM-1, compared to a healthy control subject, to assess whether the subject has, or has a risk of developing, acute kidney injury.
• BUN blood urea nitrogen
• the efficacy of the 15-PGDH inhibitors can be assessed in various animal models.
• Animal models for acute kidney injury include those disclosed in e.g., Heyman et ak, Contrin. Nephrol., 169:286-296 (2011); Heyman et ak, Exp. Opin. Drug Disc., 4(6): 629-641 (2009); Morishita et ak, Ren. Fail., 33(10): 1013-1018 (2011); Wei Q et ak, Am. J. Physiol. Renal Physiol., 303(1 l):F1487-94 (2012).
• the efficacy of treatments may be measured by a number of available diagnostic tools, including physical examination, blood tests, measurements of blood systemic and capillary pressure, proteinuria (e.g., albuminuria), microscopic and macroscopic hematuria, assessing serum creatinine levels, assessment of the glomerular filtration rate, histological evaluation of renal biopsy, urinary albumin creatinine ratio, albumin excretion rate, creatinine clearance rate, 24-hour urinary protein secretion, and renal imaging (e.g., MRI, ultrasound).
• the amount of 15-PGDH inhibitor administered to the subject can be an amount effective to induce endogenous renal PGE2 levels of the subject.
• the amount of 15-PGDH inhibitor administered to the subject can be an amount effective to induce renal vasodilatation, enhance resistance to hypoxia, improve renal hemodynamics, decrease renal oxidative stress, reduce renal inflammation, and preserve renal function.
• the amount of 15-PGDH inhibitor administered to the subject is an amount effective to reduce malondialdehyde (MDA) and NGAL levels, attenuate medulla tubular damage, reduce medulla acute tubular necrosis (ATN) and apoptosis, reduces induction of high-mobility group box 1 (HMGB1) and proinflammatory cytokines, induce renal EP4 PGE2 receptors and A2A adenosine receptors in vascular smooth muscle cells that regulate renal arterioles, increase renal cAMP, AMP, and adenosine levels, and/or inhibit induction of creatinine and KIM-1.
• MDA malondialdehyde
• NGAL levels attenuate medulla tubular damage
• ATN medulla acute tubular necrosis
• HMGB1 high-mobility group box 1
• proinflammatory cytokines induce renal EP4 PGE2 receptors and A2A adenosine receptors in vascular smooth muscle cells that regulate renal
• the pharmaceutical composition may be formulated into a parenteral or oral dosage form.
• the solid dosage form for oral administration may be manufactured by adding excipient, if necessary, together with binder, disintegrants, lubricants, coloring agents, and/or flavoring agents, to the 15-PGDH inhibitors and shaping the resulting mixture into the form of tablets, sugar-coated pills, granules, powder or capsules.
• the additives that can be added in the composition may be ordinary ones in the art.
• examples of the excipient include lactose, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, silicate and the like.
• Exemplary binders include water, ethanol, propanol, sweet syrup, sucrose solution, starch solution, gelatin solution, carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl starch, methylcellulose, ethylcellulose, shellac, calcium phosphonate and polypyrrolidone.
• the disintegrant examples include dry starch, sodium arginate, agar powder, sodium bicarbonate, calcium carbonate, sodium lauryl sulfate, stearic monoglyceride and lactose. Further, purified talc, stearates, sodium borate, and polyethylene glycol may be used as a lubricant; and sucrose, bitter orange peel, citric acid, tartaric acid, may be used as a flavoring agent.
• the pharmaceutical composition can be made into aerosol formulations (e.g., they can be nebulized) to be administered via inhalation ⁇
• the 15-PGDH inhibitors described herein may be combined with flavoring agents, buffers, stabilizing agents, and the like and incorporated into oral liquid dosage forms such as solutions, syrups or elixirs in accordance with conventional methods.
• One example of the buffers may be sodium citrate.
• Examples of the stabilizing agents include tragacanth, acacia and gelatin.
• the 15-PGDH inhibitors may be incorporated into an injection dosage form, for example, for a subcutaneous, intramuscular or intravenous route by adding thereto pH adjusters, buffers, stabilizing agents, relaxants, topical anesthetics.
• pH adjusters and the buffers include sodium citrate, sodium acetate and sodium phosphate.
• stabilizing agents include sodium pyrosulfite, EDTA, thioglycolic acid and thiolactic acid.
• the topical anesthetics may be procaine HC1, lidocaine HC1 and the like.
• the relaxants may be sodium chloride, glucose and the like.
• the 15-PGDH inhibitors may be incorporated into suppositories in accordance with conventional methods by adding thereto pharmaceutically acceptable carriers that are known in the art, for example, polyethylene glycol, lanolin, cacao butter or fatty acid triglycerides, if necessary, together with surfactants such as Tween.
• pharmaceutically acceptable carriers for example, polyethylene glycol, lanolin, cacao butter or fatty acid triglycerides, if necessary, together with surfactants such as Tween.
• the pharmaceutical composition may be formulated into various dosage forms as discussed above and then administered through various routes including an oral, inhalational, transdermal, subcutaneous, intravenous or intramuscular route.
• the dosage can be a pharmaceutically or therapeutically effective amount.
• a therapeutically effective dosage amounts of the 15-PGDH inhibitor may be present in varying amounts in various embodiments.
• a therapeutically effective amount of the 15-PGDH inhibitor may be an amount ranging from about 10-1000 mg (e.g., about 20 mg-1,000 mg, 30 mg-1,000 mg, 40 mg-1,000 mg, 50 mg- 1,000 mg, 60 mg-1,000 mg, 70 mg-1,000 mg, 80 mg-1,000 mg, 90 mg-1,000 mg, about 10- 900 mg, 10-800 mg, 10-700 mg, 10-600 mg, 10-500 mg, 100-1000 mg, 100-900 mg, 100-800 mg, 100-700 mg, 100-600 mg, 100-500 mg, 100-400 mg, 100-300 mg, 200-1000 mg, 200- 900 mg, 200-800 mg, 200-700 mg, 200-600 mg, 200-500 mg, 200-400 mg, 300-1000 mg, 300-900 mg, 300-800 mg, 300-700 mg, 300-600 mg, 300-500 mg, 400 mg-1,000 mg, 500 mg-1,000 mg
• the 15-PGDH inhibitor is present in an amount of or greater than about 10 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg. In some embodiments, the 15-PGDH inhibitor is present in an amount of or less than about 1000 mg, 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg, or 100 mg.
• a therapeutically effective dosage amount may be, for example, about 0.001 mg/kg weight to 500 mg/kg weight, e.g., from about 0.001 mg/kg weight to 400 mg/kg weight, from about 0.001 mg/kg weight to 300 mg/kg weight, from about 0.001 mg/kg weight to 200 mg/kg weight, from about 0.001 mg/kg weight to 100 mg/kg weight, from about 0.001 mg/kg weight to 90 mg/kg weight, from about 0.001 mg/kg weight to 80 mg/kg weight, from about 0.001 mg/kg weight to 70 mg/kg weight, from about 0.001 mg/kg weight to 60 mg/kg weight, from about 0.001 mg/kg weight to 50 mg/kg weight, from about 0.001 mg/kg weight to 40 mg/kg weight, from about 0.001 mg/kg weight to 30 mg/kg weight, from about 0.001 mg/kg weight to 25 mg/kg weight, from about 0.001 mg/kg weight to 20 mg/kg weight, from about 0.001 mg/kg weight to 30 mg
• a therapeutically effective dosage amount may be, for example, about 0.0001 mg/kg weight to 0.1 mg/kg weight, e.g. from about 0.0001 mg/kg weight to 0.09 mg/kg weight, from about 0.0001 mg/kg weight to 0.08 mg/kg weight, from about 0.0001 mg/kg weight to 0.07 mg/kg weight, from about 0.0001 mg/kg weight to 0.06 mg/kg weight, from about 0.0001 mg/kg weight to 0.05 mg/kg weight, from about 0.0001 mg/kg weight to about 0.04 mg/kg weight, from about 0.0001 mg/kg weight to 0.03 mg/kg weight, from about 0.0001 mg/kg weight to 0.02 mg/kg weight, from about 0.0001 mg/kg weight to 0.019 mg/kg weight, from about 0.0001 mg/kg weight to 0.018 mg/kg weight, from about 0.0001 mg/kg weight to 0.017 mg/kg weight, from about 0.0001 mg/kg weight to 0.016 mg/kg weight, from about
• the therapeutically effective dose may be 0.0001 mg/kg weight, 0.0002 mg/kg weight, 0.0003 mg/kg weight, 0.0004 mg/kg weight, 0.0005 mg/kg weight, 0.0006 mg/kg weight, 0.0007 mg/kg weight, 0.0008 mg/kg weight, 0.0009 mg/kg weight, 0.001 mg/kg weight, 0.002 mg/kg weight,
• the effective dose for a particular individual can be varied (e.g., increased or decreased) over time, depending on the needs of the individual.
• a therapeutically effective dosage may be a dosage of 10 pg/kg/day, 50 pg/kg/day, 100 pg/kg/day, 250 pg/kg/day, 500 pg/kg/day, 1000 pg/kg/day or more.
• the amount of the 15-PGDH inhibitor or pharmaceutical salt thereof is sufficient to provide a dosage to a patient of between 0.01 pg/kg and 10 pg/kg; 0.1 pg/kg and 5 pg/kg; 0.1 pg/kg and 1000 pg/kg; 0.1 pg/kg and 900 pg/kg; 0.1 pg/kg and 900 pg/kg; 0.1 pg/kg and 800 pg/kg; 0.1 pg/kg and 700 pg/kg; 0.1 pg/kg and 600 pg/kg;
• Various embodiments may include differing dosing regimen.
• the 15-PGDH inhibitor can be administered via continuous infusion.
• the continuous infusion is intravenous.
• the continuous infusion is subcutaneous.
• the dosing regimen for a single subject need not be at a fixed interval, but can be varied over time, depending on the needs of the subject.
• a pharmaceutical composition comprising an effective amount of the 15-PGDH inhibitor is administered at least twice. In another aspect, a pharmaceutical composition is administered at least five times. In yet another aspect, a pharmaceutical composition is administered at least 10 times.
• One of ordinary skill in the art can determine how often to administer the composition based on the particular disease or disorder being treated or how the subject has responded to prior treatments. One of ordinary skill in the art can also determine when to administer a treatment relative to the time that renal injury occurs, including before, after, or both.
• the subject is treated with the 15-PGDH inhibitor prior to the renal injury.
• the subject can be treated starting at least several days before the injury or as close to several minutes before the renal injury.
• the 15-PGDH inhibitor therapy can begin at about 2 hours, 8 hours, 24 hours, or 26 hours prior to ischemic reperfusion injury.
• the 15-PGDH inhibitor can be administered at varying times and not just at about 2, 8, 24, or 26 hours prior to the renal injury.
• the range of time for treating prior to the renal injury can be from about 1.0 minutes to about 72 hours.
• the range of time for treating prior to the renal injury can be from about 10 minutes to about 48 hours.
• the range of time for treating prior to the renal injury event can be from about 30 minutes to about 24 hours.
• the subject is treated with the 15-PGDH inhibitor after the renal injury event or both before and after as described above.
• the subject can be treated starting immediately after such as several minutes after the renal injury.
• the 15-PGDH inhibitor therapy can begin at about 30 minutes, 2 hours, 8 hours, 24 hours, or 48 hours after the ischemic reperfusion injury.
• the 15-PGDH inhibitor can be administered at varying times as well.
• SW033291 a potent small-molecule inhibitor of 15- PGDH, for effects in the kidney, demonstrating that SW033291 shows potent in vivo activity in increasing endogenous renal PGE2, in mediating renal vasodilation, and in conferring renal protection against ischemic acute kidney injury (AKI).
• AKI ischemic acute kidney injury
• mice Male C57/BL6 mice (10 wk) were purchased from Orient Bio. The care of and experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee of Inje University (protocol no. 2016-010). Induction of renal IRI
• mice were anesthetized with isoflurane using a vaporizer, and bilateral renal arteries were clamped for 30 min (2, 49). After the ischemic time, clamps were released to induce blood reperfusion.
• SW033291 (5 mg/kg, Cayman, Ann Arbor, MI), indomethacin (5 mg/kg, Sigma- Aldrich), or vehicle [10% ethanol, 5% cremophor EL, and 85% D5W (5% dextrose in water)] were intraperitoneally administered three times at 1 h before, immediately after, and 12 h after AKI. Serum and kidney tissue were collected 24 h after renal IRI.
• kidney tissues ( ⁇ 20 mg) were homogenized in cold PBS containing indomethacin (10 pg/mL) and then centrifuged for 10 min at 12,000 rpm. Protein concentrations of supernatant were determined by BCA assay (ThermoFisher Scientific, Rockford, IL). The PGE2 level was measured using a PGE2 ELISA kit (R&D Systems, Minneapolis, MN) in triplicate. PGE2 levels were expressed as nanograms of PGE2 per milligram of protein.
• Renal function was assessed by determining the serum levels of blood urea nitrogen (BUN; Abeam), serum creatinine (Agilent 6410 LC-MS/MS, Agilent, Santa Clara, CA), lipocalin-2 (R&D Systems), and kidney injury molecule- 1 (KIM-1; R&D Systems) after reperfusion for 24 h. Measurement of serum creatinine was by HPLC. Serum creatinine was assessed using an Agilent 6410 LC- MS/MS system coupled with an Agilent 1200 series HPLC system (Agilent). The sample preparation for serum creatinine was that 50 pL of serum samples were mixed with 100 pL of acetonitrile that contained creatinine-d3 as an internal standard (5 pg/mL).
• the mixture was centrifuged at 13,000 rpm for 10 min after vigorous vortex, and 1 pL of supernatant was then injected into the LC-MS/MS system.
• the chromatography separation was performed on a Hypersil GOLD C18 column (150 X 2.1 mm, 3 pm, Thermo Scientific) using a mobile phase of 0.1 % formic acid solution and acetonitrile [70:30 (vol/vol)].
• the flow rate was 0.2 mL/min.
• Electrospray ionization was performed in the positive ion mode.
• the capillary voltage was set at 4,000 V.
• Nitrogen as the nebulizing gas was set at 15 psi, and the drying gas temperature was set at 300°C, with a flow rate of 6 L / min.
• the multiple-reaction monitoring mode using specific precursor/production transition was used for quantification. Detection of ions was performed by monitoring m/z 114.1 44.1 for creatinine and 117.1 77.1 for creatinine-d3.
• the collision energies were 10 and 15 eV for creatinine and creatinine-d3, respectively.
• the peak areas for all analytes were integrated automatically using Agilent Mass Hunter Analysis software (version B.01.04).
• TUNEL assay Millipore, Temecula, CA
• TUNEL-positive cells were counted in at least five separate fields (64 magnification) in the outer medulla, and the apoptosis index (in %, number of apoptosis cells/total number of cells) was calculated using GENASIS software.
• Inflammatory cytokine mRNA and protein levels were measured by real-time PCR and ELISA. Kidney tissue and serum were harvested after reperfusion for 24 h. Total RNA was extracted from frozen kidney tissue using TRIzol reagent (ThermoFisher Scientific) according to the manufacturer’s protocol. RNA was converted to cDNA using oligo-dT primers. IL-17, TNF-a, and IL-lb mRNA levels were determined by real-time PCR. Serum IL-17 (R&D Systems), TNF-a (R&D Systems), and IL-Ib (R&D Systems) were measured using commercial ELISA kits according to the manufacturer’s instructions.
• the inner arteriolar area of the outer medulla was determined using a-smooth muscle actin (a-SMA)- stained sections. Kidneys were removed without perfusion under inhalational isoflurane anesthesia, divided into three pieces horizontally, immediately fixed in 10% formalin, and then embedded in paraffin. The inner area of a-SMA-positive vessels in the outer medulla was measured using ImageJ. The results are expressed as average areas of renal arteries in the outer medulla. As a surrogate for RBF, we used noninvasive laser Doppler flowmetry (periflux system 5000, Perimed) to measure flux, placing laser-Doppler probes at a fixed position on the kidney surface and recording renal cortical measurements.
• a-SMA smooth muscle actin
• Renal-Doppler flux was measured before (1 h after administration of vehicle, indomethacin, and SW033291), during, and 24 h after renal IRI.
• the relative increase represents the percent increase in RDF from baseline to peak for each test.
• kidney tissues were harvested, homogenized in 10 volumes of 0.1 M HC1, and centrifuged for 10 min at 12,000 rpm.
• cAMP levels in kidney tissues and serum were measured using a cAMP Complete ELISA kit (Enzo Life Science, Farmingdale, NY).
• AMP and adenosine in kidney tissue were assessed by Agilent 6410 LC- MS/MS. Serum adenosine was measured using an assay kit (Abnova, Walnut, CA).
• PGE2 receptors EPi, EP2, EP3, and EP4
• adenosineA2 A receptor mRNA levels were deter- mined by real-time PCR. Their protein levels were determined by Western blot assay and immunofluorescence analysis.
• ROS reactive oxygen species
• Endogenous PGE2 levels are decreased by blocking PGE2 synthesis with NS AIDs that inhibit COX-1 and/ or COX-2 but are increased by blocking PGE2 degradation by inhibiting 15-PGDH (Fig. 1A).
• SW033291 is a potent and specific chemical inhibitor of 15-PGDH with a subnanomolar IC50 value (Fig. IB).
• Treatment of mice with SW033291 induced a dose-dependent increase in renal PGE2 at 3 h after intraperitoneal injection of 2.5 or 5 mg/kg SW033291 (Fig. 1C) and showed a peak at 1 h with 5 mg/kg SW033291 tripling endogenous renal PGE2 (Fig. ID).
• mice were subjected to 30 min of IRI and administered three doses of SW033291 (IRI-SW033291) versus vehicle (IRI-vehicle), versus indomethacin (IRI- indomethacin), or versus celecoxib (IRI-celecoxib).
• SW033291 SW033291
• vehicle IRI-vehicle
• IRI- indomethacin IRI- indomethacin
• celecoxib IRI-celecoxib
• IRI-vehicle mice exhibited significant ischemic AKI, as indicated by increases in BUN, creatinine, neutrophil gelatinase-associated lipocalin (NGAF), and KIM-1 (Fig. 1, F-I).
• IRI-SW033291 markedly protected the kidney from IRI, significantly reducing BUN, creatinine, NGAF, and KIM-1 compared with IRI-vehicle mice (Fig. 1, F-I).
• inhibition of endogenous PGE2 production with administration of either indomethacin or celecoxib significantly aggravated IRI, as reflected by the increase in BUN of the indomethacin-treated group (Fig.
• tubular epithelial cells undergo injury, apoptosis, and acute tubular necrosis.
• Postischemic congestion that persists in the outer medulla further exacerbates renal injury by worsening hypoxia.
• IRI-vehicle mice showed increased tissue congestion in the outer medulla versus sham mice. This congestion was ameliorated by treatment with SW033291 but was worsened by treatment with indomethacin (Fig. 2A).
• Histopathological assessment of IRI- vehicle revealed features of acute tubular damage with tubular dilatation, extenive tubular necrosis, and apoptosis (Fig. 2, B-E).
• SW033291 treatment markedly alleviated renal injury, reducing the histological renal injury score and the count of TUNEL-positive apoptotic cells (Fig. 2, C and E).
• high- mobility group box 1 HMGB1 promotes kidney damage after IRI and induces proinflammatory cytokines.
• SW033291 treatment reduced HMGB1 levels (Fig. 3, G and H) and blocked induction of IL- 17, TNF-a, and IL-Ib (protein only) (Fig. 3, A-F).
• treatment of IRI mice with indomethacin increased HMGB1 (Fig. 3, G and H).
• prophylactic SW0333291 protects from AKI, reducing tubular damage in the outer medulla, ATN, apoptosis, HMGB1, and downstream inflammatory cytokines that promote kidney damage after IRI.
• 15-PGDH inhibition induces renal vasodilatation in the outer medulla concomitant with induction of a PGE7/EP4 receptor and adenosine/ A?
• a receptor signaling pathway 15-PGDH inhibition induces renal vasodilatation in the outer medulla concomitant with induction of a PGE7/EP4 receptor and adenosine/ A?
• SW033291 increases in cortical RDF- inferred RBF at 24 h were paralleled by findings of significantly increased renal arteriolar area in the outer medulla of SW033291 -treated mice at 24 h post- IRI (compared with both post-IRI- vehicle-treated mice and sham mice; Fig. 4, C and D). Again, in contrast, both indomethacin or celecoxib administration reduced RDF (Fig. 4, A and B). In summary, these findings suggest that SW033291 increased RBF via a PGE2-mediated vasodilatory mechanism.
• PGE2 induces cAMP levels by signaling via EP2 and EP4 receptors, a pathway that is well characterized as inducing vasodilation in the renal afferent arteriole.
• cAMP a potential downstream mechanism for the persistent SW033291- induced increase in RDF-inferred RBF at 24 h post-IRI.
• both vehicle- and indomethacin-treated mice showed reduced renal cAMP versus sham mice (Fig. 5A).
• cAMP levels at 24 h were also elevated over sham mice in IRI-SW033291 -treated mice (Fig. 5A).
• SW033291 -treated mice also showed increased levels of the cAMP breakdown product AMP (Fig. 5B).
• an additional vasodilatory molecule, adenosine was also decreased in the kidney at 24 h after IRI, and, like cAMP, this decrease was also reversed in mice treated with SW033291 (Fig. 5C).
• Increased adenosine was, furthermore, detectable at 24 h post-IRI in serum SW033391-treated mice (Fig. 5D).
• SW0332391 also induced the adenosine A2 A receptor (compared with both sham and IRI mice) (Fig. 5, E and F), with immunohistochemistry localizing the upregulated adenosine A2 A receptors to the membrane of a-SMA-positive vascular smooth muscle cells that directly regulate constriction or dilation of renal arterioles (Fig. 5G).
• SW033291 and indomethacin had no effect on levels of EP2 and EP3 receptors (Fig. 6, B and C).
• EP4 receptors induced by SW033291 were localized to the membrane of a-SMA-positive vascular smooth muscle cells that directly regulate constriction or dilation of renal arterio- les (Fig. 6G).
• induction of renal vasodilation by 15-PGDH inhibition was well correlated with increased PGE2 levels at 1 h post administration of drug, and, at 24 h, it was well correlated with induction of downstream mediators that included cAMP, AMP, adenosine, and adenosine A2 A and EP4 receptors, with induction of both EP4 and A2 A receptors targeted to vascular smooth muscle cells and with EP4 function required for drug activity.
• IRI-SW033291 (Pre) provided somewhat less protection from reduction of RDF- inferred RBF versus IRI-SW033291 (Pre + Post) (Fig. 7F).
• Pretreatment with a single 15-PGDH inhibitor dose attenuates AKI-induced oxidative stress and blocks injury-induced increases in renal PGE2
• MDA oxidative stress
• a single pre-IRI dose of SW033291 induced an early PGE2 peak just before IRI and was then sufficient to substantially block both of the later post-IRI peaks of PGE2 (Fig. 8E).
• the single pretreatment dose of SW033291 also significantly decreased both renal and serum PGE2 levels at 24 h (Fig. 8, E and F).
• pretreatment with SW033291 increased pre-IRI levels of both EP4 and A2 A receptors (Fig. 8, G and H).
• induction of endogenous PGE2 by administration of a prophylactic 15-PGDH inhibitor before IRI increases EP4 and A2 A receptors, induces vasodilatation, attenuates post-IRI oxidative stress, and, thereby, reduces multiple markers of renal injury.
• SW033291 15-PGDH inhibitor
• Fig. 4 renal hemodynamics
• Fig. 8A decreased induction of oxidative stress
• Fig. 3 reduced induction of inflammation
• Figs. 1 and 2 attenuated multiple markers of renal damage
• Figs. 1 and 2 preserved renal function
• SW033291 in preventing renal injury is likely to be an on-target effect due to modulation of PGE2, as efficacy of SW033291 was blocked by inhibiting EP4 signaling with ONO-AE3-208 and as treatment with indomethacin, a COX antagonist, and celecoxib, a COX-2 antagonist, acted opposite to SW033291 and further exacerbated renal injury (Figs. 1, 2, and 6, H-F).
• PGE2 is known to regulate renal hemodynamics and inflammation, but its rapid degradation in vivo has been an obstacle to therapeutic applications.
• Our data demonstrate that pretreatment with a single dose of SW033291 can induce PGE2 and reduce renal damage from ischemic AKI (Fig. 7).
• ischemic AKI Fig. 7
• inhibition of 15-PGDH and increasing endogenous PGE2 before ischemic IRI provides a protective effect in the kidney via increasing renal vasodilation and RBF that would be expected to enhance oxygen delivery capacity and increase resistance to hypoxia.
• RBF is determined by the vasodilator- vasoconstriction balance, with PGE2 and adenosine both acting as significant endogenous vasoactive mediators.
• PGE2 exerts a vasodilatory effect in the kidney, and the use of NSAIDs in the early postoperative period is associated with renal dysfunction due to reduced RBF from suppression of synthesis of endogenous renal PGE2.
• Our findings are consistent with observations that in most blood vessels, the vasodilation effect of PGE2 is mediated by the EP4 receptor, which, via coupling to G as , can directly activate adenylate cyclase and cAMP production.
• mice Female C57/BL6 mice (age, 10 weeks; body weight, 20-25 g) were purchased from Orient Bio Inc. (Daejeon, Republic of Korea). Before the experiments, all mice were housed individually in standard cages and were allowed to acclimate under specific- pathogen-free conditions in the animal care facility of the College of Medicine of Inje University, Republic of Korea. The care of and experimental procedures involving the animals were approved by the Institutional Animal Care and Use Committee of Inje University (protocol no. 2018-019). Induction of CIAKI
• mice Female mice were injected with 10 gl/kg of Visipaque (iodixanol) via the tail vein.
• SW033291 (5 mg/kg; Cayman, Ann Arbor, MI, USA), PGE1 (20 mg/kg; Cayman), or PGE2 (5 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) or a vehicle (10%, ethanol; 5%, cremophor EL; and 85%, dextrose 5% in water) were intraperitoneally administered 1 h before, immediately after, and 8, 16, and 24 h after the iodixanol injection (Figure 11(C)).
• mice were treated with 0.2 mg/kg/day of ONO-AE3-208 by subcutaneous injection for 14 days. Serum and kidney tissue were collected 48 h after the iodixanol injection.
• Kidney tissues were harvested 1 h after the SW033291 injection, rinsed in ice-cold phosphate-buffered saline (PBS) containing indomethacin (10 pg/mL), and snap-frozen in liquid nitrogen.
• PBS ice-cold phosphate-buffered saline
• 20 mg kidney tissue was homogenized in 500 mL cold PBS containing indomethacin (10 pg/mL) using a tissue homogenizer.
• the suspension was sonicated in an ice-water bath for 1 min using cycles of 10 s of sonication with 10 s of cooling, and then they were centrifuged for 10 min at 12,000 rpm. The supernatant was collected for PGE-2 assay. Protein concentrations were determined by bicinchoninic acid assay (Cat. #23225, Thermo Scientific). The PGE2 level in the supernatant was measured using a PGE2 enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN, USA) in triplicate. PGE-2 levels were expressed as ng of PGE2/mg protein. Assessment of renal function
• Renal function was assessed by determining the serum levels of creatinine (Arbor Assays, Ann Arbor, MI, USA), NGAL (R&D Systems), and KIM-1 (R&D Systems) at 48 h after the iodixanol injection.
• Kidneys were harvested at 48 h after the CM injection, fixed in 4% phosphate- buffered formalin, and embedded in paraffin. To evaluate necrosis, 5 mm thick paraffin sections were stained with hematoxylin and eosin. Tubular injury was scored semi- quantitatively according to a system by a pathologist who examined at least 20 separate fields (400x magnification) in the outer medulla, which is the zone most sensitive to ischemic injury. The scoring system was as follows: 0, no damage; 1, patchy isolated unicellular necrosis; 2, tubular necrosis ⁇ 25%; 3, tubular necrosis 25-50%; and 4, tubular necrosis > 50%.
• TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
• TUNEL-positive cells were counted in at least five separate fields (640x magnification) in the outer medulla, and the apoptosis index (%, number of apoptosis cells/total number of cells) was calculated using GENASIS software.
• hRPTECs Human renal proximal tubular epithelial cells
• PCS-400-010TM Manassas, VA, USA
• PCS-400-030TM Renal Epithelial Cell Basal Medium
• PCS -400- 040TM Renal Epithelial Cell Growth Kit
• the blue MTT formazan precipitate was dissolved in 100 mL dimethyl sulfoxide.
• the absorbance at 540 nm was measured with a multi-well plate reader.
• Cell viability was expressed as a percentage of the no- treatment cells, as the mean value ⁇ standard deviation of the six independent experiments.
• the hRPTECs were pelleted by centrifugation at 1800 rpm for 10 min and incubated with annexin V fluorescein isothiocyanate and propidium iodide using an Apoptosis Detection Kit I (#556547, BD Biosciences, San Jose, CA, USA) according to the manufacture’s instruction. Then quantification was conducted using a FACSC flow cytometer with Cell Quest software (BD Biosciences).
• kidney tissues were harvested, fixed in 4% phosphate- buffered formalin, and embedded in paraffin.
• the inner arteriole area of the outer medulla was determined using a-SMA-stained sections. They were incubated for 1 h with an a-SMA antibody. 3,30-diamino- benzidine (0.7 g/tablet; Sigma- Aldrich) was added, followed by washing three times with PBS for 1 min each. After counterstaining with Mayer’s hematoxylin, the inner areas of a-SMA-positive vessels in the outer medulla (25x magnification) were measured using ImageJ software. The results were expressed as the average area of all of the renal arteries in each outer medulla section.
• Total RBF was assessed by measuring renal Doppler flux using noninvasive laser Doppler flowmetry (PeriFlux System 5000, Perimed AB, Sweden). Laser Doppler probes were placed on the kidney surface to measure the renal flux. The flux was measured 48 h after CM administration. The relative increase represented the percentage increase in renal blood flow from baseline to peak for each test. Statistical significance was set as p ⁇ 0.05.
• AMP adenosine monophosphate
• Results are presented as mean ⁇ standard error of the mean. Statistical analyses were performed with one- way analysis of variance followed by the Bonferroni post-test when three or more experimental groups were compared. Values of p ⁇ 0.05 were considered indicative of statistical significance.
• CIAKI is occurred in mice with intravenous injection of visipaqueVR (iodixanol )
• Visipaque While Xenetix and Visipaque have the same iodine concentration, Visipaque has a relatively lower osmolality and a higher viscosity than Xenetix (Fig. 10(A)). When compared with normal control, Xenetix showed a significant increase in Cr only; NGAL and KIM-1 did not show significant differences. On the other hand, Visipaque showed elevation in all three renal damage markers, Cr, NGAL and KIM-1, when compared with normal control ( Figure 10(C-E)). Furthermore, Visipaque showed a significantly higher necrosis and apoptosis shown by Renal injury score and TUNEL assay than nor- mal control (Fig. 12). Therefore, it can be said that Visipaque, an isosmolar and high viscosity agent, successfully induced CIAKI in mouse, and thus we chose Visipaque as the contrast media for CIAKI mouse model.
• creatinine, neutrophil gelatinase- associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1) levels were significantly increased in CM-treated mice (CM j vehicle; creatinine, 62 ⁇ 0.02 mg/dL [normal] vs.
• SW033291 treatment in CIAKI mice led to marked reductions in the levels of creatinine, NGAL, and KIM-1 (creatinine, 1.94 ⁇ 0.24 mg/dL [CM j vehicle] vs. 1.10 + 0.11 mg/dL [CM j SW033291], p ⁇ 0.05; NGAL, 299.71 ⁇ 38.64 ng/mL [CM J vehicle] vs.
• 15-PGDH inhibitor ameliorates renal necrosis and apoptosis in CIAKI
• mice kidneys In the gross findings of the mice kidneys, two groups, those treated with CM j vehicle and CM j PGE1, showed prominent vascular congestion (red blood cells sludging and medullary hyperemia) in the outer medullary region compared to the normal group, whereas two other groups, those treated with CM j SW033291 and CM j PGE2, showed less-congested outer medullary areas (Fig. 12A). In the microscopic findings of the mouse kidneys, CM j vehicle mice showed distinct tubular dilation, necrotic cells, and loss of brush border compared to normal renal tissue (Fig. 3B).
• the microscopic renal injury score of the SW033291 administration group was significantly lower than that of the CM j vehicle mice (1.90 + 0.10 (CM j vehicle) vs. 0.53 + 0.16 (CM j SW033291), p ⁇ 0.001; Fig. 12(B,Q).
• CM Jr PGE2 also showed significantly lower renal injury scores than the CM j vehicle group, but significantly higher than the SW033291 administration group (0.53 + 0.16 [CM Jr SW033291] vs. 1.55 + 0.14 [CM j PGE2], p ⁇ 0.001). No reduction in renal injury score was observed in the PGE1 group (Fig. 12(B,C)).
• TUNEL terminal deoxy-nucleotidyl transferase dUTP nick end labeling
• 15-PGDH inhibitor protects human renal proximal tubular epithelial cells from iodixanol- induced apoptosis
• CM J vehicle vs. 10.06 ⁇ 0.85%
• CM J SW033291 [CM J SW033291], p ⁇ 0.001).
• the PGE2 group tended to have a lower apoptotic rate than the CM £ vehicle group (25.78 ⁇ 2.17% [CM J vehicle] vs. 19.43 ⁇ 1.38% [CM J PGE2], p 1 ⁇ 4 0.069), but this was not statistically significant.
• SW033291 and PGE2 treatment groups SW033291 had a significantly higher anti-apoptosis effect (10.06 ⁇ 0.85% [CM £ SW033291] vs. 19.43 ⁇ 1.38 [CM J PGE2], p ⁇ 0.05; Fig. 13C).
• 15-PGDH inhibitor induces renal vasodilation via the PGE2 receptor 4-adenosine monophosphate-adenosine pathway in the outer medulla
• SW033291 treatment in CIAKI mice significantly increased the average renal arteriole area in the outer medulla compared to untreated CIAKI mice (683.63 ⁇ 111.11 pm 2 [CM £ vehicle] vs. 1132.97 ⁇ 159.86 pm 2 [CM J SW033291], p ⁇ 0.05; Fig. 14(A,B)).
• CIAKI mice exhibited a decrease in RBF, but SW033291 treatment significantly prevented the reduction of RBF by CM injection (360.0 ⁇ 24.86 [CM J vehicle] vs. 635.2 ⁇ 11.10 [CM J SW033291], p ⁇ 0.001; Figs. 14(C,D)).
• EP1 increased in the CM ]r vehicle group, but not in the SW033291, PGE1, or PGE2 groups (Fig. 15(A)). There were no differences in the expression level of EP2 between the groups (Fig. 15(B)). However, the SW033291 group showed significantly lower EP3 expression than the CM group (1.10 ⁇ 0.03-fold [CM £ vehicle] vs. 1.00 ⁇ 0.02-fold [CM J SW033291], p ⁇ 0.05; Fig. 15(C)). The EP4 expression level was significantly increased only in the SW033291 group (1.09 ⁇ 0.02- fold [CM £ vehicle] vs.
• Visipaque a CM with high viscosity and iso-osmolality
• CM viscosity is a key element in the pathophysiology of CIAKI, and when CM is administrated in a dehydrated state, fluid viscosity increases exponentially and flow through medullary tubules and vessels decreases, which increases the duration of contact of CM to tubular cells, thereby increasing renal tubular toxicity.
• Creatinine is a biomarker that reflects the kidney’s ability to excrete waste, while NGAL and KIM-1 suggest that the kidney has under- gone a tubular injury. Therefore, we can assume that PGE1, PGE2, and the 15-PGDH inhibitor all have a protective effect in the excretory function against CM, but only PGE2 and the 15-PGDH inhibitor have a protective effect against tubular toxicity.
• PGE1 had no protective effect against cellular toxicity, and PGE2 showed only a minimal effect, much less than that of the 15-PGDH inhibitor. Therefore, the protective effect on the renal tubular cells against CM could be better achieved by inhibiting the 15-PGDH to block the catabolism of the endogenous PGE2, rather than administering exogenous PGE2.
• CM is also known as a toxic agent that decreases renal blood flow and increases vasoconstriction in many studies.
• Our renal hemodynamic study also showed that CM has obviously decreased renal blood flow (Fig. 14).
• this deteriorating effect of CM on renal hemodynamics was definitely reversed by the administration of PGE2 or 15-PGDH inhibitor, but not by PGE1.
• 15-PGDH inhibitor has increased renal vasodilation more than that of CM group, confirmed by measuring the size of arterioles.
• the analysis of vasoactive substances to increase the renal vasodilation showed that both adenosine, involved in renal blood vessel expansion, and its precursor, AMP, were increased in the 15-PGDH inhibitor or PGE2 administration group than CM group.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Urology & Nephrology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=77391654

Family Applications (1)

Country Status (7)

Cited By (5)

Citations (2)

Family Cites Families (3)

• 2021
  • 2021-02-22 JP JP2022549924A patent/JP2023515081A/ja active Pending
  • 2021-02-22 KR KR1020227032520A patent/KR20230011910A/ko not_active Withdrawn
  • 2021-02-22 CA CA3168728A patent/CA3168728A1/en active Pending
  • 2021-02-22 EP EP21756279.2A patent/EP4106748A4/en not_active Withdrawn
  • 2021-02-22 WO PCT/US2021/019084 patent/WO2021168430A1/en not_active Ceased
  • 2021-02-22 MX MX2022010258A patent/MX2022010258A/es unknown
  • 2021-02-22 AU AU2021224268A patent/AU2021224268A1/en active Pending

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events